3331
8 hours ago
BIEL GONNA RUN LIKE 2021!
Everything is falling into place just like 2021. A new distribution partner for the USA will be announced soon (replacing the KT deal from 2021). OTC bull market runs are fueled by the Fed cutting interest rates, and the Fed is now forecast to cut several times this year. Falling interest rates indicate a more accommodative money policy which makes investors more interested in the higher risk/higher reward stocks found on the OTC. The last time this happened, BIEL ran more than 1,600% to .0088. The previous BIEL runs coincided with similar OTC bull markets in 2017, 2014 and 2009.
BIEL + Viant + VLMS: Smart Relief Alliance
Transforming Non-Opioid Pain Relief into Scalable Digital Health
Executive Summary
ActiPatch by BioElectronics Corp is a clinically validated, FDA-cleared wearable using pulsed electromagnetic field (PEMF) therapy for chronic pain relief. In partnership with Viant Medical and VLMS Global Healthcare, ActiPatch will be scaled, digitally enhanced, and positioned for insurance reimbursement—creating an end-to-end solution for non-opioid pain management.
Integrated Value Proposition
This collaboration merges:
1) BIEL's proprietary PEMF tech and clinical data
2) Viant's expertise in smart device engineering, mobile integration, and manufacturing scalability
3) VLMS’s healthcare reimbursement infrastructure, coding expertise, and market entry support
Together, they’ll deliver a connected, AI-powered therapy platform that meets regulatory standards and market demand for low-cost, non-pharma alternatives.
Product & Platform Snapshot
ActiPatch and RecoveryRx devices are designed for chronic pain such as back, joint, and post-operative discomfort. They are safe for long-term use, with no drug interactions and FDA clearance for over-the-counter availability. The new connected platform will feature mobile app integration, sensors, HIPAA-compliant data tracking, and remote care capabilities.
Business Model
Revenue will be generated through:
1) Device sales ranging from $50–$100, bundled with app access
2) Monthly subscriptions ($5–$10) for AI dashboards and clinical tools
3) Clinical bundles for post-op and rehabilitation use cases
4) Licensing of de-identified health data for pharma and academic research
5) Strategic B2B partnerships with hospitals, retail chains, and telehealth networks
Financial & Market Forecast
Year 1: 100,000 users and an average revenue of $40 per user, total revenue is projected at $4 million.
Year 2: 500,000 users at $40 per user yields $20 million.
Year 3: 1 million users at $40 per user drives $40 million in revenue.
The projected device profit margin is 80%, or $40 per unit sold. Growth will be supported by low customer acquisition cost through chronic pain communities and retail channels, while long-term value is increased by subscription, device upgrades, and recurring care models.
Market Opportunity
The U.S. chronic pain market is valued at $80.92 billion in 2025 and expected to grow to $96.53 billion by 2030. Globally, the PEMF therapy device market is forecasted to expand from $755.82 million in 2024 to $1.19 billion in 2033—driven by remote therapy demand, aging populations, and opioid-free treatment trends. Meanwhile, digital health apps are growing more than 18% annually, and the bioelectronic wearables space is expected to hit $18 billion by 2028.
Strategic Contributions
BioElectronics Corp (BIEL)
Owns the IP and PEMF technology
Provides clinical studies and FDA clearances
Maintains regulatory leadership for OTC access
Viant Medical
Designs and builds connected smart devices
Leads firmware and app development
Ensures compliance, scalability, and optimized form factor
Bridges hardware development and BIEL’s legacy leadership through Dr. Sree Koneru
VLMS Global Healthcare
Crafts CMS coding strategy for reimbursement
Operates billing, claims management, and provider onboarding
Executes go-to-market strategy via Keith Nalepka’s retail expertise and investor relations
Supplies data infrastructure and facilitates hospital/insurance partnerships
Competitive Differentiation
This alliance brings the only FDA-cleared OTC PEMF wearables with true clinical backing to market as connected, AI-enabled solutions. With physician integration and smart analytics, it delivers precision care and positions itself as a scalable, credible alternative to opioids—ready to align with fitness trackers, remote care platforms, and institutional channels.
APPLE + BIEL = BIELIONAIRES!
Integrating an intelligent ActiPatch/RecoveryRx system with a device like the Apple Watch, or similar smartwatches (Google Pixel Watch, Samsung Galaxy Watch, Garmin, Fitbit, etc.), is not only feasible but would be a highly effective way to achieve the "intelligent, adaptive pain management system" vision.
Here's how this integration would work and why it's a strong approach:
Leveraging the Smartwatch as the Data Hub and AI Processor (or Gateway):
Instead of building all the sensors and processing power directly into the tiny, disposable ActiPatch, the smartwatch can serve as the central brain and data collector.
1. Sensor Data Acquisition:
* Existing Smartwatch Sensors: Modern smartwatches already possess many of the physiological sensors needed for comprehensive pain assessment:
* Heart Rate (HR) & Heart Rate Variability (HRV): Excellent indicators of stress, pain, and recovery.
* Activity Tracking (Accelerometer, Gyroscope): Detects movement, sleep patterns, and activity levels, crucial for understanding pain context and recovery progress.
* Skin Temperature: Apple Watch Series 8 and newer, and all Ultra models, have wrist temperature sensing, which can indicate inflammation or illness.
* Sleep Tracking: Provides insights into sleep quality, which is vital for pain management and recovery.
* Blood Oxygen (SpO2): While less directly tied to pain, it's another overall health metric.
* ECG (Electrocardiogram): Can detect irregular heart rhythms, which can be linked to stress or other underlying conditions.
* ActiPatch with Minimal Sensors: The ActiPatch itself would primarily need to focus on its core function:
* Bluetooth Low Energy (BLE) Module: This is critical for communicating with the smartwatch. The ActiPatch would transmit its operational status (e.g., "on/off," "battery level") and potentially receive new PEMF parameters from the smartwatch.
* Basic Confirmation Sensor (Optional but helpful): A simple contact sensor could confirm the patch is properly applied to the skin, preventing wasted therapy.
* Modulatable PEMF Generator: The most important internal modification would be to allow the ActiPatch to receive commands from the smartwatch to dynamically adjust its PEMF output (frequency, intensity, pulse duration). This means the ActiPatch wouldn't just be "on" or "off" at a fixed setting, but could deliver a nuanced, AI-guided therapy.
2. Data Flow and AI Processing:
* Smartwatch to iPhone (or Android Phone): Health data from the Apple Watch (or other smartwatches) is already seamlessly synced to the Health app on the user's iPhone.
* Dedicated ActiPatch/RecoveryRx App: A dedicated app would be developed for the iPhone (and potentially a companion Watch app for simpler interactions). This app would:
* Access HealthKit Data: Through Apple's HealthKit framework, the app would securely access the relevant physiological and activity data collected by the Apple Watch (with user permission).
* Integrate User Input: Allow users to log subjective pain levels, specific activities that trigger pain, medication intake, and other qualitative data.
* Host the AI Engine: The AI algorithms (Machine Learning, Reinforcement Learning) would run within this app or leverage cloud computing if more intensive processing is required. This AI would:
* Correlate Data: Analyze the Watch's objective sensor data with the user's subjective pain input.
* Identify Pain Patterns: Learn what physiological and activity patterns correlate with pain onset, increase, or decrease for that specific individual.
* Generate Adaptive PEMF Prescriptions: Based on the AI's real-time assessment of pain and recovery, it would determine the optimal PEMF settings.
* Send Commands to ActiPatch: Via BLE, the app would then send commands to the modified ActiPatch, instructing it to adjust its PEMF parameters.
3. User Experience and Feedback Loop:
* Smartwatch Notifications: The Apple Watch could deliver subtle haptic notifications or on-screen alerts, for example:
* "Pain spike detected: ActiPatch intensity increased."
* "Consistent use is improving recovery. Keep it up!"
* "Time to apply your ActiPatch for optimal overnight recovery."
* Watch App Interface: A simplified Watch app could allow users to quickly:
* See current pain status.
* Manually trigger or stop therapy.
* Log quick pain severity ratings.
* iPhone App Dashboard: The main iPhone app would provide a rich dashboard with:
* Historical pain trends vs. therapy application.
* Insights into correlations (e.g., "Your pain tends to be lower after consistent therapy and X hours of sleep.").
* Progress reports shared with healthcare providers (with consent).
Why this integration is powerful:
* Reduced Hardware Complexity for ActiPatch: The ActiPatch remains small and lightweight, as it doesn't need to contain a full suite of sensors or heavy processing. This keeps manufacturing costs down and maintains its comfortable wearability.
* Leverages Existing Ecosystem: Taps into the vast user base and mature health tracking capabilities of smartwatches and smartphone health platforms (like Apple HealthKit).
* Rich Data Stream: Smartwatches provide a continuous and diverse stream of physiological and activity data, which is crucial for training and operating sophisticated AI models for personalized pain management.
* User Familiarity: Users are already accustomed to interacting with smartwatches and health apps, reducing the learning curve.
* Continuous Monitoring: Unlike a device that only measures when you activate it, the smartwatch provides 24/7 background monitoring, allowing the AI to gather comprehensive context.
In essence, the Apple Watch (or similar) would act as the "eyes and ears" and much of the "brain" for the ActiPatch system, allowing the ActiPatch to become a highly responsive and personalized "treatment delivery arm."
The technical indicators come first - the Golden Cross and the Blue Sky Breakout. Then the fundamentals kick in (Taiwan, VA, Veterinary, New Zealand...). BIEL is a Reddit investors dream. Once they become aware of BIEL (via the financial press), the pps will rocket, product sales will soar, and we'll be celebrating like 2021!
BIEL COULD HIT COPPER IN THE "BLINK OF AN EYE"!
The first catalyst will likely be the announcement of a new partner for the USA (GOOD RIDDANCE KT), which could come any day! The key statement from the annual report is "The Company has focused attention on seeking a distribution and licensing partner for the OTC US market". If investors value this partnership at $300k (and add it to the $496k of mostly international revenue reported for 2024), the pps gets out of the trips. If the investor valuation is $1 million, then the pps hits COPPER! The last time this happened (KT deal in 2021), BIEL soared 1,600%.
BIEL GOES VIRAL AT PPS = .003!
Market cap = $75 million at pps = .003, which would generate massive press (free marketing/advertising) in the news and financial media when they report that the pps increase is better than the gains in Amazon and Apple (3,000% over the past 10 years). It would solve all of BIEL's problems and create numerous opportunities for the company. The Reddit crowd would be all over it (generating massive free online marketing/advertising). If the company then declares profits would be used for a share buyback program (after paying off the loans), the pps would soar ($1+) and the rise would be sustained.
BIEL - SIMPLE, CLEAR PATH TO SUCCESS
BIEL is undervalued at just $5 million with $496,000 in revenue (2024), compared to companies that boast billion-dollar valuations despite generating less revenue. For instance, QUBT holds a $2.3 billion market cap on just $373,000 in revenue. As awareness grows around the advantages of PSWT/PEMF technology and the vast multi-billion-dollar, drug-free pain management market—where FDA-cleared ActiPatch, RecoveryRx, and RecoveryRx Veterinary products are poised to lead—BIEL's potential for massive growth becomes undeniable.
In Q3 2021, BIEL achieved profitability with $22,381 in earnings on $414,700 in revenue, including over $100,000 in COVID relief funds. With its exceptionally low operating costs and efficient business model, profitability is within reach. A $1.5 million annual revenue—or a $400,000 quarter—could be the tipping point, potentially driving the stock price to $0.01 and increasing by $0.01 for every additional $2.5 million in annual revenue (P/E = 100). Moreover, the company's $40 million tax-loss carryforward ensures that the first $40 million in profits remain tax-free, accelerating the road to sustained profitability. If management hints at profitability in Q1 2025 or suggests Q2 will be profitable, investor confidence will grow and the PPS would hit COPPER, solving key challenges, and unlocking new opportunities.
BIEL IS THE NEXT BITCOIN (ROI)!
The Bitcoin return on Investment (ROI) is about 40,000% over the past 10 years. BIEL will go viral at PPS = .003, as it would generate massive press (free marketing/advertising) in the news and financial media when they report that the PPS increase is better than the gains in Amazon and Apple (3,000% over the past 10 years). It would solve all of BIEL's problems and create enormous opportunities for the company. The Reddit crowd would be all over it - generating a Bitcoin like frenzy and more free marketing/advertising - which could catapult the PPS to .04 (40,000% ROI on my .0001 shares)!
OTC stocks are heating up, as they always do when a bull market matures. While most trip zero stocks are scams or shells, BIEL is the ONLY trip zero stock that has been in business for over 20 years (without ever doing a reverse split) and has a real product (with five FDA clearances) that gets rave reviews!!!
BIEL’s GROWTH PATH AND MILESTONE TARGETS
1️⃣ Move out of trips when hints of a major deal emerge—triggering technical indicators like the Golden Cross (0.0004) and Blue Sky Breakout (0.0005).
2️⃣ PPS = 0.003: A 3,000% surge, surpassing Apple & Amazon’s 10-year growth rate, following a U.S. distributor announcement—then going viral.
3️⃣ PPS = 0.01: A 10,000% increase, a $400k revenue quarter (or hint of) should do it!
4️⃣ PPS = 0.04: A 40,000% surge, backed by $10M profit, akin to Bitcoin’s performance over the past 10 years.
5️⃣ PPS = 0.10: A 100,000% increase, requires $25M profit (P/E = 100).
The Easiest, Fastest & Most Likely Path to Success
🔹 Generate a $400K revenue quarter—or persuade investors it’s imminent—reaching copper.
🔹 Achieve a $1.5M annual revenue—or convince markets it’s incoming.
🔹 Management hints profitability for Q1 or Q2 2025, reinforcing investor confidence.
🔹 Investors value the new U.S. partnership at $300K, bringing PPS above 0.001—or at $1M, launching it to copper.
BIEL’s Prospectus & Long-Term Outlook
BIEL’s lean OEM business model is positioning the company for rapid profitability. Considering investor projections:
1️⃣ $800K annual revenue: A significant revenue jump from recent years, moving PPS beyond trips.
2️⃣ $1.5M revenue or a $400K quarter: Likely to secure cash flow positivity & profitability, boosting PPS to copper.
3️⃣ 1,000,000%+ upside potential is unmatched by any other stock on the market.
4️⃣ $40M tax-loss carryforward—meaning the first $40M in profits will be tax-free, accelerating net earnings growth.
Final Outlook: BIEL Could Be the Next Viral Phenomenon
At PPS = 0.003, BIEL could dominate headlines—its market cap hitting $75M alongside comparisons to Apple and Amazon’s long-term gains. Investor enthusiasm could fuel a run toward $1+, sustained by a share buyback program (after the loans are paid off).
If momentum continues:
✅ PPS = 0.10: 100,000%, requires $25M profit (P/E = 100—amplified by tax advantages).
✅ PPS = $1: 1,000,000% increase, sustained by a share buyback program (after the loans are paid off).
TURN $1 INTO $1,000,000 - BIEL IS IDEAL FOR A REDDIT SURGE
The 1,000,000%+ upside potential is unmatched by any other stock on the market. BIEL could hit copper in the blink of an eye - a $400k revenue quarter (or hint of) should do it!
With approximately 15 billion BIEL shares locked in the hands of dedicated long-term investors—who, like me, may never sell—the available float shrinks to around 10 billion shares. That presents a unique opportunity for accumulation on the open market. In fact, it would take a relatively modest sum—just $2,000,000 at the current $0.0002 per share (1,000 Redditers investing $2,000)—to gain significant control over BIEL's available shares.
Investor sentiment surrounding BIEL is strong, with thousands closely watching its price action. The moment the PPS ticks upward, a surge of buyers is likely to follow. Given that the majority of outstanding shares are held tightly, the price could skyrocket upon ignition. The classic supply-demand imbalance favors an explosive move (SQUEEZE!), as demand outstrips the limited availability of shares.
The price appreciation wouldn't wait for full accumulation—rather, it would likely rise steadily as the 10 billion shares are scooped up. The real question is how high it could go. With BIEL catching the attention of retail investors—including the Reddit crowd—a substantial rally isn't out of the question.
We've seen similar explosive moves in stocks like GameStop (GME), where retail enthusiasm and strategic buying pressure drove the price to unprecedented highs.
With rising revenues, especially a $400,000 quarter (or hints of) that would likely produce a profit, the PPS would soar. A move to $0.10? Certainly within reach.
BIEL is positioned for explosive growth. The key lies in executing strategic partnerships, revenue milestones, and market positioning—paving the way for one of the biggest potential stock surges in recent history. At PPS = $10 (after the share buyback), every $1 invested in .0001 shares will be worth $1,000,000!
VETERANS ADMINISTRATION (HUGE)!
RecoveryRx now available through prosthetics for pain management, ortho, PT (courtesty of edbi):
VA providers now have access to recently FDA-approved non-opioid, non-invasive pain management device through RecoveryRx. RecoveryRx produces an electromagnetic field at the point of pain that changes how cells communicate pain. Research, technical information and studies available at www.RecoveryRx.co. It is an amazing device, unlike TENS units, RecoveryRx reduces pain without any kind of electrical stimulation feeling for the veteran. The antenna lasts 30 days, all Ortho, pain management, and PT providers can work through prosthetics (RecoveryRx is on the FSS) to get these on their patients for feedback and widespread use at the VA.
Courtesy of Av8tor65:
Just a quick note to share that the Central Texas VA Hospital is now prescribing the RecoveryRx device. Earlier today, I gave a Recovery Rx device to a co-worker who was heading to a pain management appointment at the VA and encouraged him to take the device with him to show his doctor. Turns out, the doctor was already familiar with RecoveryRx and is actively prescribing it. The physician agreed to prescribe one for my co-worker as well, who, notably, is a Purple Heart recipient. Great to see continued momentum and recognition for this technology in veteran care settings. Millions of devices could be distributed throughout the VA network. I will be next......
CORNERING THE BIEL MARKET - A STRATEGIC PERSPECTIVE:
In the early 1980s, the Hunt brothers famously cornered the silver market, accumulating nearly one-third of the global silver supply. Their massive investment drove prices from $2/ounce to $50/ounce, but when they couldn't meet margin calls, the market collapsed.
Applying the Strategy to BIEL
Unlike silver, BioElectronics Corporation (BIEL) presents a unique opportunity with significantly lower capital requirements and no margin borrowing risk. Assuming 15 billion shares are in strong hands, that leaves approximately 10 billion shares available for accumulation—equivalent to a mere $2 million investment at $0.0002 per share.
Market Dynamics & Potential Price Action
Low Capital Requirement: Compared to the billions needed to manipulate the silver market, cornering BIEL’s available shares would require only pocket change relative to institutional investments.
No Margin Borrowing Risk: The Hunt brothers’ downfall was leverage—with BIEL, strategic accumulation would be fully capital-backed, mitigating collapse risk.
Upward Price Movement: As the 10 billion shares are acquired, price appreciation is inevitable—the key question is how much and how fast.
Catalysts for Growth
Reddit & Retail Investor Interest: If traction builds among the retail investing community (similar to past explosive penny stock movements), momentum could snowball rapidly.
Institutional Engagement: Increased distribution and medical adoption of RecoveryRx could attract larger institutional players, further stabilizing upward movement.
Conclusion
With strategic share accumulation, increasing revenues, and market excitement, BIEL could experience exponential appreciation—presenting a rare opportunity for early movers to corner a low-cap market with limited financial risk. Just sayin'...something for the BIEL VENTURE CAPITAL HEDGE FUND stakeholders to consider.
BIEL VENTURE CAPITAL HEDGE FUND
KEY STAKEHOLDERS: DR. DON BUFORD, DR. SREE KONERU, KEITH NALEPKA, OREL HERSHISER
Each key stakeholder should see RecoveryRx not just as a product, but as an opportunity for professional leadership and financial breakthrough. By distributing RecoveryRx and investing in BIEL shares, they cement their status as visionaries in medical innovation and create a powerful wealth-building opportunity in the highly lucrative medical device market.
Projected Outcomes:
1. Increased distribution of RecoveryRx among medical professionals.
2. Surge in BIEL stock accumulation, leading to exponential valuation growth.
3. Strengthened brand credibility through endorsements from industry leaders.
Executive Summary:
This plan aims to leverage the influence of key industry leaders—Keith Nalepka, Dr. Sree Koneru, Dr. Don Buford, and other medical professionals—to expand the distribution of RecoveryRx and drive investment in BIEL. By capitalizing on their networks and credibility, we can create a powerful movement that positions BIEL for exponential growth.
Strategic Business & Investment Framework for Key Stakeholders:
By leveraging their professional credibility, industry influence, and financial foresight, these individuals can accelerate RecoveryRx distribution, boost BIEL stock valuation, and secure first-mover advantages in a high-growth opportunity.
1. Keith Nalepka – Strategic Leadership & Global Expansion
As President of VLMS Global Healthcare and an ex-BIEL VP of Sales, Keith and VLMS are perfectly positioned to scale RecoveryRx distribution through major healthcare networks.
Immediate Strategy: Structure partnerships between BIEL and VLMS, integrating RecoveryRx into existing medical supply chains.
Investment Thesis: Keith’s direct experience with BIEL grants unique insights into its growth potential, making stock accumulation (by Keith and VLMS) a strategic financial move.
2. Dr. Sree Koneru – Technology & Medical Validation
As a former BIEL VP of Engineering and a high-level executive at Viant Medical, Dr. Koneru is critical for reinforcing technical credibility and expanding RecoveryRx adoption.
Industry Influence: His engineering expertise strengthens the case for RecoveryRx’s scientific legitimacy.
Stock Investment Strategy: His position on BIEL’s board aligns him with long-term value appreciation, making increased share accumulation (by Sree and Viant) a logical financial step.
Institutional Scaling: Collaborate with Viant Medical for large-scale manufacturing and distribution expansion.
3. Dr. Don Buford – Medical Advocacy & Market Expansion
Dr. Buford’s endorsement of RecoveryRx has sparked significant industry interest, as seen in his LinkedIn engagement.
Momentum Tactic: Capitalizing on enthusiastic responses to his post by establishing a formal RecoveryRx distributor network.
Revenue-Driven Investment Strategy: Encouraging physicians who show interest in distribution to also purchase BIEL shares, ensuring dual financial benefit.
MLB Connection Activation: Utilizing his ties within sports medicine to promote RecoveryRx adoption among MLB players and athletic trainers.
4. Orel Hershiser – MLB Endorsement & High-Profile Investment
Orel Hershiser, already a BIEL shareholder, can serve as a sports industry bridge, bringing in MLB investors and sports medicine practitioners.
Investor Activation Plan: MLB players invest in BIEL, seeing long-term financial growth potential in its expanding medical footprint.
Distribution Expansion Strategy: Partnerships with MLB training facilities and medical staff, integrating RecoveryRx into sports recovery protocols.
Media & Branding Enhancement: High-profile endorsements and interviews to accelerate visibility and credibility.
Leveraging Their Collective Influence:
By expanding RecoveryRx distribution and strategically accumulating BIEL shares, Keith (and VLMS), Sree (and Viant), Dr. Buford, and Orel Hershiser position themselves as industry pioneers, driving both medical innovation and wealth-building opportunities in the highly lucrative medical device market.
BIEL IS SIMPLE TO ANALYZE!
Q3 2021 was BIEL's only profitable quarter ($22,381) with $414,700 revenue (including $100k+ in covid relief funds). PROFITABILITY IS VERY CLOSE! Seems like $1.5 million annual revenue (or a $400k quarter) should do it, due to BIEL's extremely low operating costs and business model. Then the corresponding pps should hit .01 - and increase .01 for each additional $2.5 million annual revenue (P/E = 100). The $40 million tax-loss carry forward will make the first $40 million in profits tax free and accelerate the path to profitability. KISS - KEEP IT SIMPLE STUPID! 💋
THIS DISTINGUISHED GROUP COULD EASILY BECOME BIELIONAIRES!
1) LAST WEEK KEITH NALEPKA (EX-BIEL VP SALES) WAS PROMOTED TO PRESIDENT OF VLMS GLOBAL HEALTHCARE.
2) LAST WEEK A PRESITGIOUS GROUP OF DOCTORS/SURGEONS/MEDICAL WORKERS RAVED ABOUT RECOVERYRX.
https://www.linkedin.com/posts/donbufordmd_ever-heard-of-a-tens-unit-or-a-nerve-stimulator-activity-7333861518729465856-vdpb?utm_source=share&utm_medium=member_android&rcm=ACoAAD5fnnMBgcCqTZjoHiMob3xCmYJyZQN5d7A
3) RECENTLY DR. SREE KONERU (EX-BIEL VP ENGINEERING) WAS PROMOTED TO A HIGH-LEVEL MANAGEMENT POSITION AT VIANT MEDICAL AND SOON AFTER WAS APPOINTED TO THE BIEL BOARD OF DIRECTORS.
I think Keith and Sree already own over 100,000,000 shares and that Orel Hershiser also owns a significant amount. If they were to accumulate more, and the rest of the doctors/surgeons mentioned above invested accordingly, they could make BIEL run well over 10,000% (COPPER) in a matter of days/weeks - and much higher if Dr. Buford, Orel Hershiser and Keith Nalepka could tap into their MLB connections (or get some players to invest)!
DISTRIBUTORS AND INVESTORS ARE THE KEY TO SUCCESS!
It was great to see the fabulous replies to Dr. Buford's post. Responses like the following are the key to success for BIEL:
"I'm very excited to look into the possibility of carrying these devices and becoming a distributor."
While all the responses to Dr. Buford's post were excellent, this one deserves particular attention:
"I am also a believer! This thing simply works. I have no conflicts of interest, other than a small margin when my patients purchase one. It is truly impressive how well these work."
While the "small margin" can be remedied by increasing the unit cost, a better solution would be if the sellers and distributors purchased shares while the share price is so ridiculously low. The return on investment for the shares would be exponential (Amazon/Apple/Netflix - like) when the company reports (or hints about) increased revenues.
THE "WELLNESS MARKET" MAY BE THE BIGGEST OF ALL!
There were comments in the Dr. Buford discussion about potential uses for Actipatch/RecoveryRx that have not been FDA cleared. There have been many suggestions and testaments recently for using Actipatch/RecoveryRx "off label" as a "wellness" product (CHA-CHING $$$ without FDA complications - BIEL already has enough FDA clearances!). People have successfully used it for menstrual pain, migraines, diabetic neuropathy, restless leg syndrome (RLS affects 10% of adults worldwide), opioid reduction, bladder issues, etc. There is also huge potential for prostate issues (non-cancerous), as there is evidence that PEMF/PSWT therapy helps with Benign Prostatic Hyperplasia (BPH) symptoms.
❤️32 REASONS TO LOVE BIEL❤️
1. It's a real company with real products.
2. The company is not burning $$$ millions every quarter trying to get a product through the FDA wringer. They've accomplished FDA clearance (5) already.
3. The company is very close to profitability every quarter. BIEL will likely be profitable soon, if not already (a $400K revenue quarter should do it).
4. There is no toxic debt. The company is not sinking under death spiral financing.
5. Actipatch has thousands of excellent, mostly 5-star customer reviews.
6. The $40 million tax-loss carry forward will make the first $40 million in profits tax free and accelerate the path to profitability.
7. Insider Buying - Significant insider loans (and recent roll-overs) are equivalent.
8. Technical indicators (Golden Cross, Blue Sky Breakout, etc.) turning positive. Every bull run starts with this.
9. Bare bones expenses: about $750k/year for GENERAL AND ADMIN EXPENSES (salaries, utilities, R&D, Advertising, etc) with a burn rate of about $220k/year for Other Gen and Admin Expenses.
10. New utility patent (pending) for chronic pain inflammation (vagus nerve) - HUGE.
11. Accepted for use by the Veterans Administration.
12. BIEL has 5 FDA clearances with more pending.
13. Insurance coverage is expanding - currently covered by the UK National Health Service (and Taiwan?).
14. In business for over 20 years
15. Never reverse split.
16. Rapidly expanding in the veterinary/pet market - RECOVERYRX-VETERINARY could be a GOLDMINE!
17. New contract/partner rumors swirling.
18. Fed forecast to cut interest rates five times this year, which greatly benefits OTC stocks like BIEL.
19. The potential is mind-boggling - especially if Actipatch is identified as a "wellness product" for the applications not currently covered by the FDA clearances (menstrual, depression, migraines, restless leg, etc.).
20. Actipatch will be a Standard of Care product. Actipatch/RecoveryRX have a massive potential market - essentially every human on the planet AND their pets/animals (RecoveryRX Veterinary)!
21. The higher margin RecoveryRX is available by prescription.
22. A new distribution partner for the USA will be announced soon. The last time this happened (2021) BIEL surged 1,600%.
23. BIEL is optimizing the Netflix business model.
24. BIEL COULD HIT COPPER IN THE "BLINK OF AN EYE"!
25. PPS = .001. $800k annual revenue gets the pps out of the trips.
26. PPS = .003. BIEL GOES VIRAL (equivalent to 3,000% 10-year ROI gains in Apple and Amazon)!
27. PPS = .01. Achieved with $400k revenue quarter.
28. PPS = .02. 20,000% increase (with $5 million profit, P/E = 100).
28. PPS = .03. 30,000% increase (with $7.5 million profit, P/E = 100).
29. PPS = .04. 40,000% increase (akin to 10-year ROI in Bitcoin, with $10 million profit (P/E = 100).
30. PPS = .10. Achieved with $25 million profit (P/E = 100).
31. PPS = $1. After loans are paid off and a stock buyback is initiated.
32. See 1 - 31!
ACTIPATCH WILL BE A "STANDARD OF CARE" PRODUCT!
While Bitcoin has no underlying value (it's a speculative bubble like Dutch tulips in the 17th century or abstract art), Actipatch has FDA clearances for the treatment of knee, back, wrist, hips, ankles, plantar fasciitis, carpal tunnel and all musculoskeletal pain. Actipatch has incredible value, especially at the low price of $35 - with a much longer battery life (720 hours or several months if extended with the on/off button) than the competition! The Actipatch FDA clearances allow it to be sold over the counter (without a prescription). The higher margin RecoveryRX applications (post operative pain, edema, wound care, etc.) require a doctor order. Add in RecoveryRx-Veterinary and you have over 10 billion potential repeat customers - every adult and pet on the planet - every month!
BIEL's EASIEST, FASTEST AND MOST LIKELY PATH TO SUCCESS IS:
1) to generate a $400k revenue quarter (or convince investors it's imminent) - which would achieve cash flow positive/profitability and increase the pps to copper.
2) to generate a $1.5 million revenue year (or convince investors it's imminent).
3) if management hints Q1 2025 was profitable, or Q2 will be.
4) if investors value the new distribution and licensing partner for the OTC US market at $300k (gets the pps out of the trips when added it to the $496k of mostly international revenue reported for 2024). If the investor valuation is $1 million, then the pps hits COPPER!
BIEL:
1) gets out of the trips when some hints are dropped - triggering the Golden Cross (.0004)/Blue Sky Breakout (.0005) technical indicators.
2) PPS = .003 = 3,000% increase (better than Apple and Amazon over the past 10 years), when the new US distributor is announced - and then GOES VIRAL!
3) PPS = .02 = 20,000% increase with $5 million profit/P/E = 100.
4) PPS = .04 = 40,000% increase with $10 million profit/P/E = 100 (equivalent to Bitcoin over the past 10 years).
5) PPS = .10 with $25 million profit/P/E = 100.
RECOVERYRX-VETERINARY COULD/SHOULD BE A GOLDMINE!
The Assisi Loop sells over 300/month just on Amazon @ $329, with 1/20 the battery life. Assisi Loop customers are paying the equivalent of over $6,000 when you factor in the additional cost and lower battery life, but Assisi customers seem happy to pay it based on the numerous 5-star reviews. RecoveryRx/Veterinary should be sold as a two/pack - one applied on the vagus nerve and the other attached on the area of pain.
INSIDER BUYING - HUGE!
The best indicator for predicting a company's future is insider buying. The extensive insider loans (and recent roll-overs) identified in BIEL's annual reports basically have the same effect as insider buying. Insider loans are actually better, as they allow the company to avoid toxic lenders. The insider investment/market cap ratio for BIEL is higher than any other company on the market.
BIEL OPTIMIZING THE NETFLIX BUSINESS MODEL!
Netflix has increased over 325,000%, from .35 (on 10/9/02) to about $1,150 today!
1) Product price is about the same and Actipatch lasts as long as a monthly Netflix subscription (much longer when the on/off switch is utilized).
2) Actipatch/RecoveryRX has much larger market potential. While both are available to virtually every human on the planet, RecoveryRX Veterinary is also available to their pets! Also, the high margin RecoveryRX is available by prescription, and the "wellness market" is available for the aches and pains not covered by FDA clearances (menstrual, migraine, restless leg, depression, etc. - simply attach it over the vagus nerve!).
3) BIEL's product profit margins are much higher as their operating costs are virtually nothing compared to Netflix (no movie studios and actors required to constantly put out new content).
DR. OZ
The Dr. Oz effect will be interesting, considering his recent appointment as Administrator of the Centers for Medicare and Medicaid Services. When Actipatch was featured on the Dr. Oz show, it achieved record sales and sold out the inventory.
BIEL + DR. OZ = $$$ (see 6:25 mark)
https://youtu.be/qVvS2dC2-1s?si=OqYNG3__BRlz-NFF
PROSPECTUS
BIEL's low-cost OEM business model has put the company in position to be profitable soon such that if investors project for 2025:
1) Annual revenue of $800k - this will be a significant increase from the previous three years and get the pps out of the trips;
2) $1.5 million annual revenue (or a $400k quarter) - this will likely achieve cash flow positive/profitability and get the pps to copper.
3) BIEL's prospects for achieving a 1,000,000% increase in pps are better than any other company on the market right now!
4) The path to profitability will be accelerated by the tax-loss carryforward of about $40 million (no tax on first $40 million profit).
5) BIEL GOES VIRAL AT PPS = .003!
Market cap = $75 million at pps = .003, which would generate massive press (free marketing/advertising) in the news and financial media when they report that the pps increase is better than the gains in Amazon and Apple (3,000% over the past 10 years). It would solve all of BIEL's problems and create numerous opportunities for the company. The Reddit crowd would be all over it (generating massive free online marketing/advertising). If the company then declares profits would be used for a share buyback program (after paying off the loans), the pps would soar ($1+) and the rise would be sustained.
6) PPS = .02 = 20,000% increase - requires $5 million profit (P/E = 100). Profits will be accelerated by the tax loss carryforward (no tax on first $40 million profit)!
7) PPS = .10: Requires $25 million profit (P/E = 100). Profits will be accelerated by the tax loss carryforward (no tax on first $40 million profit).
BIEL IS THE NEXT AMAZON/APPLE (in terms of ROI)!
When BIEL hits .003, the return on investment for a .0001 buy (for those of us fortunate enough to get them recently) will be about the same as the 10-year ROI (3,000%) for Amazon and Apple (stocks I sold too soon). Microsoft 10-year ROI is ONLY 900%. BIEL can hit .003 in IN THE BLINK OF AN EYE, as $1.5 annual revenue (or a $400k quarter) should do it (due to BIEL's extremely low operating costs and business model). There are many indications that this will be accomplished soon, if it hasn't been already! We know that Taiwan, the VA, South Africa and Bulgaria are in progress, as is RecoveryRx-Veterinary in Europe (with the USA pending). Canada is expanding, New Zealand sales started March 1 and hopefully Australia will soon follow.
BIEL is a Venture Capitalist Dream! The opportunity to get in on the "next big thing", but with a company that has been in business for over 20 years (rather than a start-up). BIEL is probably the closest that any of us will get to having a venture capital kind of opportunity.
1) BIEL products have Standard of Care pain management potential for every adult and pet on the planet.
2) BIEL has 5 FDA clearances (with more pending) and the products work extremely well (some say like a miracle).
3) Upside ROI is huge (>10,000%) with minimal downside risk!
4) BIEL should be able to use their China manufacturer to ship directly to their international distributors and Viant for their USA sales to avoid tariffs.
BIEL HITS COPPER WHEN THE FOLLOWING OCCURS!
pps > .001 after management drops some positive hints. The Golden Cross (already achieved) and Blue Sky Breakout will get the technicians/chartists/Reddit crowd attention and the pps out of the trips;
pps > .01 after management drops some positive hints that convinces investors that break even/cash flow positive (annual rev = $1.5 mil) will be achieved, combined with the momentum from a 2021 like OTC run (fueled by the Reddit crowd);
pps > .04 after pr indicates the annual revs from Taiwan (in progress) can be valued at $10 mil+;
pps > .08 after pr indicates the annual revs from the VA (in progress) can be valued at $10 mil+;
pps > .12 after pr indicates the annual revs from RecoveryRx Veterinary (pending) can be valued at $10 mil+;
pps > .16 after pr indicates the annual revs from new contracts (distributors, partners, New Zealand, etc.) can be valued at $10 mil+;
Above pps values are based on P/E = 100
For P/E = 200, pps = .32
For P/E = 300, pps = .48
pps > $1 after loans are paid off and a stock buyback is initiated.
CATALYSTS (Details):
1) USA distribution partner announcement.
2) Taiwan - there are over 80 public hospitals and over 400 private hospitals in Taiwan. They have national health insurance and are rated the world's number one health system.
Assume 100 Taiwan hospitals order 100 Actipatch/RecoveryRx per month @$100 each for BIEL:
$100 x 100 hospitals x 100 x 12 mo = $12,000,000 rev/year.
Using profit = $10 mil and P/E = 100: PPS = .04.
Note: RecoveryRx Veterinary also appears to be in play in Taiwan.
3) 1000 Veterinarian Clinics (USA):
Conservatively assume each office orders 10/mo. @ $100 each for BIEL (Vet sells for $200, a bargain compared to Assisi):
1000 x 100 x 10 x 12 = $12,000,000 rev/year.
Note: RecoveryRx Veterinary also appears to be in play internationally.
4) Veterans Administration: There are over 1,000 VA facilities in the U.S. Conservatively assuming 100 VA hospitals order 100 RecoveryRx per month ($100 each for BIEL):
100 x 100 x 100 x 12 = $12,000,000 rev/year.
Sub-total for VA + VET = Using $20 mil (profit) and P/E = 100: PPS = .08!
TOTAL (Taiwan + VA + Veterinary + applying the tax loss carryforward):
pps = .12 (P/E = 100)
pps = .24 (P/E = 200)
pps = .36 (P/E = 300)
Additional revenue could be generated from new FDA clearances, vagus nerve patent, NPA, UK/Australia contract rumor, RecoveryRx Veterinary international sales, New Zealand, etc. Initiating a stock buyback program after all of the loans are paid off would propel the pps much higher (pps = $1).
BIEL FACT CHECK:
1) The basher/ambulance chasers repeatedly complain about the nearly 25 billion shares outstanding, but they can't provide a single reason why. It's irrelevant as it is accounted for in the VALUATION (pps) - 25 billion shares @.0002 = $5 million is the same valuation as 1 million shares at $5/share. NVIDIA has the same number of shares outstanding as BIEL, Apple and Amazon will soon have billions more (after the next split), and nobody is concerned! The stock market is all about valuation (outstanding shares x pps) - you buy if you think a stock is under-valued and sell if you think it is over-valued. Only amateurs/newbies/bashers do not understand this simple concept. Right now, investors feel BIEL is fairly valued between $2.5 - 5 million, but if news develops where investors feel $1 billion is fair value, you will see the BIEL pps rise accordingly (pps = .04). Some have tried to dispute this by changing the subject to dilution. BIEL has not diluted significantly in many years, and there is no indication it will in the future. The low pps is actually an advantage at this point, as it makes BIEL affordable to any investor (big and small). If you have $1,400 to invest, would you rather own 7 million shares of BIEL or 1 share of O'Reilly Auto Parts? The Reddit crowd would definitely choose BIEL.
2) BIEL's valuation is currently $5 million for revs of $496k (2024), which is undervalued compared to stocks with billion-dollar valuations but less revenue than BIEL (QUBT, for example, with a market cap of $2.2 billion on revenues of $373k). When people become aware of the benefits of PSWT/PEMF and the huge multi-billion-dollar drug free pain management market - that desperately needs FDA cleared Actipatch/RecoveryRx/RecoveryRx Veterinary- BIEL will SOAR!
3) BIEL has been in business for over 20-years and has NEVER done a reverse split, which is VERY IMPRESSIVE!
4) Supply/Demand - the majority of the outstanding shares are in tight hands, so the pps will move up like a rocket after ignition, as the supply of available shares will be less than the demand (SQUEEZE!). Shareholders can help fuel the blast off by locking up their shares with "good until cancelled sell orders" (@$1) so their shares cannot be borrowed by the short sellers, thereby further reducing the supply.
BUYOUT
Right now, I doubt anything under $50 million would be considered (accounting for loans, etc.). That's out of my range, but in the future - after the pps increases, loans are paid off and a share buyback is implemented - I could see a point where a group of shareholders could get together and leverage their shareholdings to make an offer. Years ago, Simpsonly and some other shareholders made an offer to Andy but were turned down. Not sure if Orel Hershiser was part of that group, but he is rumored to be a shareholder and a big fan of the products (would be a great influencer for BIEL).
LICENCE/PARTNER/MERGER?
The Signal Relief Patch (in business for a little over a year) costs about twice as much as the Actipatch, but is much less effective at reducing pain and will probably never gain FDA approval. However, they do have lots of money for marketing and advertising - their ads are on national TV every day, along with on-line media. They might be a good partner for Actipatch - we could use their advertising/marketing budget, and they could use Actipatch (integrated with their patch) to make their device more effective at reducing pain. It could work the way the KT licence was supposed to. Signal Patch is private now, so a merger with BIEL would give them quick access (compared to an IPO) to the stock market, where their venture capitalists would get a better return on their investment (than stay private).
REVIEWS (5 STAR)
BIEL technology works and sells WHEN people become aware of it and where to buy, as demonstrated by the Recovery Wave, which is Amazon's "Overall Pick" and a hot seller (over 700 per month) with rave reviews (STANDARD OF CARE like), such as:
Green Light ON...Pain is Gone!
Reviewed in the United States on May 5, 2025
I've been using this for a few years now and works great on my lower back and knee pain. I put one on my lower back before golf each week and zero pain. Highly recommend and don't leave home without it.
5.0 out of 5 stars Verified Purchase
Amazingly effective for such a little, simple device
Reviewed in the United States on October 29, 2024
I knew about these loops because a vet used an Assissi loop, this one’s big brother, to heal my agility dog’s back end when she sprained it badly. So I thought I’d try this smaller, cheaper and more portable unit to help with healing and pain from a fractured sacrum that had been hurting for 9 months. I had to leave this device on for several hours at a time. After about two hours on I noticed pain diminishing the first time I wore it. Now after about a month of sporatic use (ie, only when I had pain or did activities I knew that brought on pain) I am living mostly pain free! I also have been doing my PT exercises and they help too, but the pain wasn’t diminishing much with exercises alone. Another advantage of this unit is that it doesn’t shoot a current through your body like a tens unit, which I find very disagreeable. I will keep a KT Wave Recovery loop on hand for times when I need it.
RecoveryRX is also getting great reviews (May 2025):
Steven Ray Garcia Owner/Operator-Sandlot Medical: "This is a great product. I work with a couple top Plastic Surgeons in Scottsdale, and Recovery RX is part of their breast augmentation recovery protocol."
IS BIEL THE NEXT MSFT?
Those that bought one share of Microsoft at the IPO price of $21 saw their investment increase to $210,000 recently (10,000 X). Someone buying 1 million shares of BIEL @.0002 would see their $200 investment grow to $2,000,000 (pps = $2) with equivalent growth. Is this possible? Absolutely, after BIEL becomes profitable, pays off their loans and then implements an aggressive stock buyback program!
1) Re: "read the financials" posted ad-nauseum - Hindsight is 20/20 vision - the past financials are what provided this opportunity to buy BIEL at this low price before it becomes the next Amazon, Apple, Netflix, Bitcoin...Investing is about the future, not the past!
"I got vision and the rest of the world wears bifocals" - Butch Cassidy.
2) Re: "shareholders will sell at the first opportunity" posted ad-nauseum - To the contrary, shares are currently in "strong hands" and thousands of investors are watching BIEL and will jump in at the first uptick (Golden Cross/Blue Sky Breakout) as evidenced by BIEL routinely being at the top of the Breakout, Most Read, Most Viewed and Most Active boards. The demand for shares will outweigh the supply well into COPPER!
3) The bashers appear to be lonely people starved for conversation and attention that they can only find on this board - SO SAD!
BIEL GONNA RUN SOON! Then what will the loser bashers do? GetDelirious, Lifetime Loser, Crapsule, G-stain, Puff Dad (FREAK OFF!), fArt, et al., are lonely losers starved for attention that they seemingly can only find on this board - SO SAD! It would be so interesting to meet the people who devote their MISERABLE lives to bashing a small company trying to achieve the American Dream. Who does that?
4) Misanthrope and GetDelirious are cowardly, gutless COMMUNIST moderators that are SO TERRIFIED OF GETTING SCHOOLED they delete all of my posts! Meanwhile, they mumble and pollute the board with blithering word salads like:
"you can get a bullshit answer of suitable bullshittiness to match the high level of bullshit in the rest of your post.
Keep up the fine bullshittery".
5) The ex-Mayflower mover (who constantly claims others lack intelligence) has still not provided a shred of evidence to support his repeated accusations that I "lie and deceive." It's telling when an angry ex-insurance office staffer is so frustrated with his life - and such a LOSER in the eyes of his professor wife - that he spends his retirement slandering posters on an anonymous investment board! Now he claims to have studied electrical engineering in college (HILARIOUS!).
SUPPLEMENT 1 (courtesy of beacham)
I think what is happening is BIEL has ‘a deal’ w/ one of the suppliers/distributors to CMMS and/or the VA. I also think we have an emerging contract relationship w/ Viant and that is the reason Dr. Sree Koneru is on our BOD.
These presumptions (opinions) solve a lot in terms of logistics and financials. For manufacturing, it removes the uncertainty of a China-based supplier of product. Taiwan is a flashpoint and relations w/ China are strained. Viant has international reach that can supply product to any of our distributors worldwide w/o all the drama and tension, not to mention shipping time, of having a manufacturer thousands of miles away in a potentially hostile situation. How this ties into the paucity of Raw Materials expenditures over the last 4 yrs is a good question. We keep CICD for the Asian distribution but should circumstances change, we have Viant. They also have a Design & Development division. It’s a smart move.
Working w/ a ‘local’ supplier to CMMS and/or the VA takes the buyout scenario off the table for now. It does, however, give BIEL some certainty in terms of revenue and, if/when announced, would do wonders for the share price.
The logistics of this are complicated, complex, time sensitive and politically charged, involving not only the nuts and bolts but official approvals as well. I think the Atlanta sites are a pilot project / launch-point to work out the myriad details. Working through a supplier who has already done the paperwork to work w/in the CMMS and/or VA bureaucracies is a huge bonus. They would ‘simply’ add our products to their catalog. Doing the legwork to make that happen would be their responsibility and thus freeing us to focus on supplying product to them for their distribution to the numerous CMMS and/or VA locations.
It would also explain having an NDA and the near total silence that ensues. Nobody needs or wants an army of bashturds crawling up your backside agitating for the impossible. The scope and magnitude of this project is enormous, beyond words. CEO Kelly Whelan has not been given enough credit, in my opinion. And all of this work must be done under the radar, by legal necessity, as per an NDA. Lots of moving parts and endless details. When CEO Kelly says they are working, I believe her.
SUPPLEMENT 2 (courtesy of beacham)
Let’s assume that BIEL will get the CMS and the VA contract. If/when that announcement(s) takes place, whether simultaneously or separately, the explosion in the share price will make Mt. Vesuvius look like a backyard firecracker on the 4th of July. Now, I ask you, would that make you stay ‘mum’ on any of the details??? Yea, me too.
The share price would not hit copper in a week. It would happen before lunch. By the time you entered an order at a specific price, the price will have jumped to the next level. Either buy at ‘market’ or forget it. The price would explode. Dare to dream and imagine.
3331 has been restricted to one post per day (for months) which is often deleted.
edbi46
17 hours ago
Stop being sarcastic, BAND AIDS!!!
For those, who, deliberately, for the sole purpose -- their AGENDA -- "INFECTED" themselves with comprehension/thinking disability virus, a repeat post!!!!!
DR. OZ on Actipatch ( 10 years ago, go to 6:25 mark ), listen and weep!!!!!!!!
https://www.youtube.com/watch?v=qVvS2dC2-1s
Now, that Dr. Oz is Tsar.......BIEL...$$$$$$$$$$$$$$$$$$$$$!!!!!!!!!!!!!!!!!!!!!!!
-----------------------------------------------------------------------------
DonJoy Store
EME Replacement Device ( FSA / HSA APPROVED!!!!!!$$$$$$$ )
https://www.donjoystore.com/donjoyr-advantage-eme-replacement-device?srsltid=AfmBOoqJL5fv-Tkyjz7NmuwFnDcBi2nm4lqHTYznN6zlx5vaKarK8IsL
------------------------------------------------------------------------------
A new over-the-counter treatment for heel pain caused by plantar fasciitis has received clearance from the United States FDA.
https://www.footandankleps.com/blog/new-wearable-therapy-provides-heel-pain-treatment
--------------------------------------------------------------------------------
Actipatch Smart Insole -- NEW & IMPROVED!!!
https://unovita.com/products/smart-insoletm-heel-pain-relief?variant=47506240471349
https://shop.renovabiomed.it/it/prodotti/3402-soletta-e-fascia-smart-insole.html?sfnsn=wa
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-------------------------------------------------------------------------
RecoveryRx now available through prosthetics for pain management, ortho, PT
Veterans Health Administration
VA providers now have access to recently FDA-approved non-opioid, non-invasive pain management device through RecoveryRx. RecoveryRx produces an electromagnetic field at the point of pain that changes how cells communicate pain. Research, technical information and studies available at www.RecoveryRx.co. It is an amazing device, unlike TENS units, RecoveryRx reduces pain without any kind of electrical stimulation feeling for the veteran. The antenna lasts 30 days, all Ortho, pain management, and PT providers can work through prosthetics (RecoveryRx is on the FSS) to get these on their patients for feedback and widespread use at the VA.
https://www.reddit.com/r/VeteransAffairs/comments/1gxclby/recoveryrx_now_available_through_prosthetics_for/?utm_source=share&utm_medium=mweb3x&utm_name=mweb3xcss&utm_term=1&utm_content=share_button
__________________________________________________
No WORD SALADS, no SUBSTANTIAL/NONE SUBSTANTIAL ACCUSATIONS, ( like LYING that he/she/it has ANY amount of shares in BIEL, PRETENDING to be shareholder........i can smell those from a mile away!!! ), did/will do any desired effect !!!!! We know they are watching BASHING work here, before the checks are being cut!!!
--------------------------------------------------------------------------------------------------------
Territory///Distributor////Products Distributed/// Website
Australia LMT ActiPatch RecoveryRx www.actipatch.com.au
Bangladesh Multiple Health Pharma ActiPatch
Bahrain STADA ActiPatch www.stada.com
Botswana Adcock Ingram ActiPatch www.actipatch.co.za
China CICD ActiPatch
Finland Kir Fix Oy ActiPatch www.kir-fix.fi
Iran Al Mutawafiqua Modern Drug ActiPatch
Ireland Inish Pharmacy ActiPatch www.inishpharmacy.com
Italy OneGlobe Bio ActiPatch/RecoveryRx www.oneglobebio.com
Jordan Al Mutawafiqua Modern Drug ActiPatch
Kuwait Modern Development ActiPatch/RRx www.mdmedical.co
Lebanon Al Mutawafiqua Modern Drug ActiPatch
Mexico Novro Med S.A. de C.V. RecoveryRx https://globaltech.com.mx/
Oman Modern Development ActiPatch/RRx www.mdmedical.co
Qatar Modern Development ActiPatch/RRx www.mdmedical.co
Saudi Arabia STADA ActiPatch www.stada.com
Spain Acuna Fombona ActiPatch www.acuna-fombona.com
Spain PRIM Group RecoveryRx www.prim.es
South Africa Adcock Ingram ActiPatch www.actipatch.co.za
Sweden Swedish Healthcare Academy ActiPatch www.actipatch.se
Taiwan Aphrodite Bio-Medical Technology ActiPatch www.abmt.com.tw
UAE Modern Development RecoveryRx www.mdmedical.co
United Kingdom Chemist4u ActiPatch www.chemist-4-u.com/
United States BioElectronics Corp RecoveryRx www.recoveryrx.co/
United States DonJoy DonJoy Advantage www.donjoyperformance.com
Yemen Al Mutawafiqua Modern Drug ActiPatch
https://www.bielcorp.com/distributors/
-------------------------------------------------------------------------------------------------------
From 3331:
BIEL 2025 - GONNA RUN!
pps > .001 after management drops some positive hint(s) - Golden Cross (already achieved) and Blue Sky Breakout gets technicians/chartists attention and pps out of the trips;
pps > .01 after management drops positive hint(s) convincing investors that break even cash flow positive (annual rev = $1.5 mil) will be achieved, along with the momentum from a 2021 like OTC run (Reddit crowd takes notice);
pps > .04 after pr indicates annual revs from Taiwan (in progress) can be valued at $10 mil;
pps > .08 after pr indicates annual revs from VA (in progress) can be valued at $10 mil;
pps > .12 after pr indicates annual revs from RecoveryRx Veterinary (pending) can be valued at $10 mil;
pps > .16 after pr indicates annual revs from new contracts (distributors, partners, etc.) can be valued at $10 mil;
pps > $1 (2026 - 2027)after loans are paid off and a stock buyback program is initiated.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175652979
-------------------------------------------------------------------------------------------------------
ATTENTION all the Respected, Smart, Intelligent Investors !!!!!!! Do your OWN, INTELLIGENT, THOROUGH DD, without ANY INFLUENCE FROM KNOWN PAID BASHERS / PUMPERS / LIARS / MANIPULAYTORS / MISINFORMERS !!!!!!!!! Make sure, if you decide to invest ( and to decide you MUST !! ) :
#1 -- Don't put all the money you are willing to invest in one basket ( buy only one stock ), be diverse......VERY IMPORTANT -- Do your OWN, INTELLIGENT DD !!!!!!!!!!!!!!!!
#2 -- If you decide/willing to buy BIEL shares, know, that this is a HIGH RETURN / HIGH LOSS RISK ratio, but a MIRACLE PRODUCT ( ACTIPATCH ) is the key !!!!
#3 -- if you decide/willing to buy BIEL shares, invest only as much as you are willing
to loose, without being hurt, FINANCIALLY !!!!!!!!!!!!!!!!!
Good luck to all !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Lets see how high our beloved BIEL gets TRUMPed/JFK JUNIORed/DR. OZed up by Jan. 1, before NOPAIN Act is activated ( and, specifically, after!!! ) !!! HEHEHE.
Here are the HARD FACTS about Bioelectronics corp ( BIEL ). below , backed by LINKS, NOT some made up LIES, BS WORD SALADS, SUBSTANTIAL/NONE SUBSTANTIAL ACCUSATIONS to DAMAGE one's IMAGE, to INFLUENCE POTENTIAL Investors to think negative about the Company's ( BIEL ) Future, to FALL for WORD SALADS of SCARE TACTICS, with an AGENDA !!!!!!!!!!!
BIEL$$$
------------------------------------------------------------------------------------------------------------
"If you’re looking for a powerful way to enhance your vitality, recover faster, and optimize your overall well-being, I highly recommend exploring PEMF therapy. It’s an investment in your health and a key component of my own personal journey towards peak performance.”
– Tony Robbins
Tony uses a high powered $25,000 PEMF machine but anyone can sample some of PEMF's capabilities with a $30 ActiPatch.
http://54.219.205.59/2023/07/17/the-energy-machine-that-powers-tony-robbins-exploring-the-transformative-power-of-pemf-therapy/
------------------------------------------------------------------------------------------------------------
Note, while NOPAIN ACT is a PREDICTION, YET, it is still a HARD FACT and VERY DOABLE!!!!!!!!
NOPAIN Act
Jan. 1, 2025
https://www.congress.gov/bill/117th-congress/house-bill/3259/text?s=2&r=1&q=%7B%22search%22%3A%22NOPAIN+ACT%22%7D
Just to highlight a few points::
(G) ACCESS TO NON-OPIOID TREATMENTS FOR PAIN.—
“(i) IN GENERAL.—
Notwithstanding any other provision of this subsection, with respect to a covered OPD service (or group of services) furnished on or after January 1, 2022, and before January 1, 2027, the Secretary shall not package, and shall make a separate payment as specified in clause (ii) for, a non-opioid treatment (as defined in clause (iii)) furnished as part of such service (or group of services).
“(ii) AMOUNT OF PAYMENT.—
The amount of the payment specified in this clause is, with respect to a non-opioid treatment that is—
“(I) a drug or biological product, the amount of payment for such drug or biological determined under section 1847A; or
II) a medical device, the amount of the hospital’s charges for the device, adjusted to cost.
“(iii) DEFINITION OF NON-OPIOID TREATMENT.
A ‘non-opioid treatment’ means—
“(I) a drug or biological product that is indicated to produce analgesia without acting upon the body’s opioid receptors; or
“(II) an implantable, reusable, or disposable medical device cleared or approved by the Administrator for Food and Drugs for the intended use of managing or treating pain;
that has demonstrated the ability to replace, reduce, or avoid opioid use or the quantity of opioids prescribed in a clinical trial or through data published in a peer-reviewed journal.”.>>>>
Ambulatory Surgical Center Payment System.—Section 1833(i)(2)(D) of the Social Security Act (42 U.S.C. 1395l(i)(2)(D)) is amended—
(1) by aligning the margins of clause (v) with the margins of clause (iv);
(2) by redesignating clause (vi) as clause (vii); and
(3) by inserting after clause (v) the following new clause:
“(vi) In the case of surgical services furnished on or after January 1, 2022, and before January 1, 2027, the payment system described in clause (i) shall provide, in a budget-neutral manner, for a separate payment for a non-opioid treatment (as defined in clause (iii) of subsection (t)(16)(G)) furnished as part of such services in the amount specified in clause (ii) of such subsection.”.
(c) Evaluation Of Therapeutic Services For Pain Management.—
1) REPORT TO CONGRESS.—
Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services (in this subsection referred to as the “Secretary”), acting through the Administrator of the Centers for Medicare & Medicaid Services, shall submit to Congress a report identifying—
(A) limitations, gaps, barriers to access, or deficits in Medicare coverage or reimbursement for restorative therapies, behavioral approaches, and complementary and integrative health services that are identified in the Pain Management Best Practices Inter-Agency Task Force Report and that have demonstrated the ability to replace or reduce opioid consumption; and
(B) recommendations to address the limitations, gaps, barriers to access, or deficits identified under subparagraph (A) to improve Medicare coverage and reimbursement for such therapies, approaches, and services.>>>>
(2) PUBLIC CONSULTATION
.—In developing the report described in paragraph (1), the Secretary shall consult with relevant stakeholders as determined appropriate by the Secretary.
(3) EXCLUSIVE TREATMENT.
—Any drug, biological product, or medical device that is a non-opioid treatment (as defined in section 1833(t)(16)(G)(iii) of the Social Security Act, as added by subsection (a)) shall not be considered a therapeutic service for the purpose of the report described in paragraph (1).
___________________________________________________________________
The Pain Relief Therapy Market is characterized by a diverse competitive landscape, with several leading companies influencing market trends and driving innovation. Notable players include:
Stimwave: Specializes in innovative neuromodulation devices designed for chronic pain management, focusing on minimally invasive procedures to enhance patient outcomes.
Merk & co: A global leader in pharmaceutical products, Merck is actively involved in developing new analgesics and expanding its portfolio to address unmet medical needs in pain management.
Sanofi: Known for its wide range of pharmaceutical products, Sanofi is committed to advancing pain relief therapies through research and strategic partnerships.
Endo Pharmaceuticals.: Focused on pain management solutions, Endo is leveraging its expertise to develop unique formulations that cater to varying patient needs.
Calmare Therapeutics: Recognized for its innovative non-invasive pain relief technology, Calmare Therapeutics is pioneering new approaches to chronic pain treatment.
Johnson & Johnson: A key player in the healthcare sector, Johnson & Johnson is expanding its pain relief offerings through a combination of product innovation and strategic acquisitions.
Abbott: Engaged in developing advanced pain relief systems, Abbott is at the forefront of creating integrated solutions that combine medical devices and pharmaceuticals.
Allergan: Known for its aesthetic and therapeutic products, Allergan is also exploring pain relief therapies, particularly in the realm of nerve block techniques.
Beiersdorf: While primarily recognized for its skincare products, Beiersdorf is venturing into the pain relief market with topical analgesics and other innovative solutions.
Hisamitsu.: A leader in transdermal drug delivery systems, Hisamitsu is focused on developing patch-based pain relief solutions.
UltraCare Pro: Specializes in therapeutic modalities that enhance pain management through non-invasive techniques.
Iskra Medical.: Develops medical devices that facilitate pain relief, particularly in physiotherapy and rehabilitation settings.
Bioelectronics Corp: Innovates in the field of electroceuticals, offering non-drug solutions for pain management .
Medline : A major player in the healthcare supply chain, Medline is expanding its product offerings to include pain management solutions.
Pfizer: Actively involved in researching and developing new pain relief medications to address chronic pain issues.
Each of these companies plays a vital role in shaping the Pain Relief Therapy Market through product innovations, market expansions, and strategic partnerships, contributing to the overall growth and development of the sector.
Moreover, consumer awareness regarding pain management options is on the rise. Patients are becoming more informed about their choices, leading to increased demand for customized solutions that cater to individual needs. This trend is prompting companies to focus on product customization and the development of tailored therapies.
Emerging technologies, such as wearable devices and Internet of Things (IoT) solutions, are also shaping the future of the Pain Relief Therapy Market. These innovations allow for continuous monitoring of patients' conditions, enabling timely interventions and adjustments to treatment plans based on real-time data.
https://www.openpr.com/news/3785778/pain-relief-therapy-market-industry-dynamics-and-contributions
__________________________________________________________________
CY 2025 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule (CMS 1809-P)
“Access to Non-Opioid Treatments for Pain Relief
…We are proposing that seven drugs and one device qualify as non-opioid treatments for pain relief, and we propose these products be paid separately in both the HOPD and ASC settings starting in CY 2025…”
https://www.cms.gov/newsroom/fact-sheets/cy-2025-medicare-hospital-outpatient-prospective-payment-system-and-ambulatory-surgical-center
CONCLUSION
"The medical device market is poised for significant growth across all major regions, driven by technological advancements, increasing healthcare spending, and a global focus on improving healthcare outcomes. London and the UK continue to position themselves as leaders in medical device innovation, while Europe remains a regulatory-driven but stable market. Asia offers the most dynamic growth opportunities, with countries like China and India playing pivotal roles. Meanwhile, the USA maintains its dominance as the largest medical device market, supported by advanced R&D and regulatory frameworks. Investors looking to capitalize on these trends should consider region-specific opportunities, keeping an eye on the evolving regulatory landscapes and technological innovations shaping the industry."
https://iotworldmagazine.com/2024/09/05/2420/a-review-of-medical-device-market-size-reports-2024-2025-in-london-u-europe-asia-and-usa-focused-on-growth-forecast-and-segments
REFERENCES
Fortune Business Insights: https://www.fortunebusinessinsights.com/
MarketsandMarkets: https://www.marketsandmarkets.com/
Mordor Intelligence: https://www.mordorintelligence.com/
Gov.UK: https://www.gov.uk/
GlobalData: https://www.globaldata.com/
TechNavio: https://www.technavio.com/
Statista: https://www.statista.com/
Emergo: https://www.emergobyul.com/
Frost & Sullivan: https://www.frost.com/
Allied Market Research: https://www.alliedmarketresearch.com/
BMI Research: https://www.bmiresearch.com/
IBISWorld: https://www.ibisworld.com/
McKinsey: https://www.mckinsey.com/
Grand View Research: https://www.grandviewresearch.com/
----------------------------------
Globe Newswire via NewsMeiaWire
Sree Koneru, PhD Joins the Board of BioElectronics Corporation
FREDERICK, MD December 3, 2024 -- (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ OTC:
BIEL a developer of medical technology products, today announces that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD.
https://www.facebook.com/story.php?story_fbid=1120914580039912&id=100063641406505
___________________________________________________
Nasdaq news:
BioElectronics Corporation Announces Utility Patent Application Filing
PUBLISHED
MAY 21, 2024 8:09AM EDT
Non-Invasive Device Addresses the Treatment of Chronic Inflammation
FREDERICK, MD - (NewMediaWire) - May 21, 2024 - BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the filing of a new USPTO utility patent application addressing the treatment of chronic inflammation. This patent application, numbered 18/667,971, was a collaborative effort of John Martinez, Kenneth McLeod, PhD, and Richard Staelin, PhD. It outlines methods, systems, apparatuses, and devices that modify the immune response through non-invasive stimulation of the vagal nerves. The application draws from the results of a recently completed double-blind, placebo-controlled, canine study, published in Veterinary Medicine and Science which demonstrated that Pulsed Short Wave Therapy (PSWT) Technology applied to the vagal nerves of dogs diagnosed with osteoarthritis resulted in significant reductions in systemic discomfort.
https://www.nasdaq.com/press-release/bioelectronics-corporation-announces-utility-patent-application-filing-2024-05-21
____________________________________________________________
This is just a few FACTS to help with INTELLIGENT DD and to INVEST in BIEL, which, i/we agree with this post worth a reasonable investment:
(https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172266874;; )
A SDVOSB Owned Exclusive Provider of RecoveryRx for VA ( Veterans ) Hospitals!!!
https://veteranrecovery.org/
Veterans, connect with us to learn more about RecoveryRx®
New PAIN RELIEF TECHNOLOGY at the push of a button!!!
https://kellycovemobility.com/rrx/
BIEL$$$
RecoveryRX Major General Livingston, a Medal of Honor recipient, who had 6 operations for back, does a fantastic job describing his experience with RecoveryRx Pain Relief!!!!!
https://youtu.be/jljs7QPX7KE
Pulsed Electromagnetic Field Enhances Caffeic Acid Phenethyl Ester-induced Death of MCF-7 Breast Cancer Cells
https://pubmed.ncbi.nlm.nih.gov/38821617/
BioElectronics’ pulsed shortwave therapy device is effective for limb pain: study says
https://www.nsmedicaldevices.com/news/bioelectronics-pulsed-shortwave-therapy-device/
ORTHOALLIANS
RecoverRX!!
https://orthoalliance.com/optimal-recovery/
MD Medical
MD Medical is the fastest growing medical company in kuwait.
SIster Company @socheck_kuwait
Kuwait, Hawally Governorate, Salmiya, Block 2, Abdullah Bin Masoud Street, Al-Ras Tower, Floor 3, Office No.B3, Kuwait City 13091
https://www.instagram.com/mdmedicalco/
___________________________________________________________
News
BioElectronics’ pulsed shortwave therapy device is effective for limb pain: study says
Staff Writer February 26, 2024
https://www.nsmedicaldevices.com/news/bioelectronics-pulsed-shortwave-therapy-device/
_________________________________________________
This is just a few FACTS to help with INTELLIGENT DD and to INVEST in BIEL, which, i/we agree with this post worth a reasonable investment:
(https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172266874;; )
A SDVOSB Owned Exclusive Provider of RecoveryRx for VA Hospitals!!!
https://veteranrecovery.org/
Veterans, connect with us to learn more about RecoveryRx®
New PAIN RELIEF TECHNOLOGY at the push of a button!!!
https://kellycovemobility.com/rrx/
BIEL$$$
RecoveryRX Major General Livingston, a Medal of Honor recipient, who had 6 operations for back, does a fantastic job describing his experience with RecoveryRx Pain Relief!!!!!
https://youtu.be/jljs7QPX7KE
________________________________________________
This is just a few FACTS to help with INTELLIGENT DD and to INVEST in BIEL, which, i/we agree with this post worth a reasonable investment:
(https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172266874;; )
A study investigating the efficacy of our FDA-cleared (human use) pulsed-shortwave-therapy (PSWT) device in initiating a systemic anti-inflammatory response to improve the functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. It was published today online in "Veterinary Medicine and Science." Medical professionals can contact us at info @newbie00 to request sample products.
Pulsed shortwave electromagnetic field therapy increases quality of life in canines with symptoms of osteoarthritics
Tanya Ella Sprunks, Kenneth J. McLeod, Richard Staelin
First published: 22 March 2024 https://doi.org/10.1002/vms3.1408
Sree Koneru and Jack Merrifield contributed equally to this study.
https://onlinelibrary.wiley.com/doi/10.1002/vms3.1408
BioElectronics’ pulsed shortwave therapy device is effective for limb pain: study says
https://www.nsmedicaldevices.com/news/bioelectronics-pulsed-shortwave-therapy-device/
Ortho Alliance, 11 Orthopedic Surgery Centers, 'Optimal Recovery' with Pre/Post-Op RecoveryRx
https://orthoalliance.com/optimal-recovery/
Smart Approach Recovery
https://recoveryrx.carrd.co/
Kelly Cove Mobility
https://youtu.be/jljs7QPX7KE
RecoveryRx Veterinary
https://rrxvet.carrd.co/
TES Veterinary Physiotherapist
https://vetphysiodevon.com/vet-recovery-rx
Actipatch Taiwan
https://www.actipatchtw.com/general-1
Actipatch Sweden
https://rehabat.se/products/actipatch-mot-muskel-och-ledsmarta-och-kna-och-ryggsmarta
Actipatch Italy
https://alaction.it/
Actipatch Bulgaria
https://actipatch.bg/
Actipatch Finland
https://www.facebook.com/watch/?mibextid=SphRi8&v=1026096241843857&rdid=0EAph2C6CZ4xryHY
ActiPatch STADA
https://www.linkedin.com/posts/kelly-whelan-5ba88115_distribution-painrelief-stada-ugcPost-7274483449602748417-__ZB/
BIEL announces publication of Canine OA Study
https://finance.yahoo.com/news/bioelectronics-corporation-announces-publication-canine-124500399.html
Vagus Nerve Patent Application Filing RecoveryRx
https://www.newmediawire.com/news/bioelectronics-corporation-announces-utility-patent-application-filing-7075138
________________________________________________
This is just a few FACTS to help with INTELLIGENT DD and to INVEST in BIEL, which, i/we agree with this post worth a reasonable investment:
(https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172266874;; )
INTRODUCING
RecoveryRx Veterinary
Drug-Free Pain Relief Device
For Indoor and Outdoor Pets
https://rrxvet.carrd.co/
Vet Recovery RX
"An innovation in drug-free pain and edema management. RecoveryRx is a class II, USA FDA-cleared, non-thermal shortwave therapy device which utilizes radio-frequency electromagnetic energy to modulate nerve activity"
https://vetphysiodevon.com/vet-recovery-rx#:~:text=An%20innovation%20in%20drug%2Dfree,energy%20to%20modulate%20nerve%20activity
Alpha Animal Rehab and Fitness is at Alpha Animal Rehab and Fitness.
Exciting news at #AARF—we have two new products to support your pup’s health and recovery: RecoveryRX and YuMove! 🐾 RecoveryRX is a wearable device that uses low-level electromagnetic therapy to help reduce pain and inflammation, perfect for dogs recovering from surgery or dealing with chronic conditions.
https://www.facebook.com/story.php?story_fbid=463227680005342&id=100089543403668&mibextid=xfxF2i&rdid=KBLw46cEZ1egeIst
PEMF Ring is Saving a 14 Year Old Labrador
https://therapyproducts.net/pemf-ring-is-saving-a-14-year-old-labrador/
Alpha Animal Rehabilitation and Fitness | NJ
Pet Service
Certified Canine Rehab Therapists helping pets with conditions/injuries/post surgery to manage pain and recover holistically through Physical Therapy
316 3rd Ave, Alpha, New Jersey 08865
https://investorshangout.com/images/MYImages/519436370_Screenshot_27-8-2024_7119_www.instagram.com.jpeg
"As the sole UK and European distributor of Recovery RX Veterinary, Tanya Sprunks offers advanced long-lasting pain relief for pets using Electromagnetic Pulse Therapy. She operates several successful clinics across Devon, focusing on Veterinary Physiotherapy."
https://www.glebevets.co.uk/services/physiotherapy/
A SDVOSB Owned Exclusive Provider of RecoveryRx for VA ( Veterans ) Hospitals!!!
https://veteranrecovery.org/
Veterans, connect with us to learn more about RecoveryRx®
New PAIN RELIEF TECHNOLOGY at the push of a button!!!
https://kellycovemobility.com/rrx/
BIEL$$$
RecoveryRX Major General Livingston, a Medal of Honor recipient, who had 6 operations for back, does a fantastic job describing his experience with RecoveryRx Pain Relief!!!!!
https://youtu.be/jljs7QPX7KE
Old sports injury trying to bench you from the summer fun? 🌞🌊 Get back in there with ActiPatch® on your team! 🌟
✅ Pain relief can be felt after just 2-3 hours
✅ Safe to use during regular physical activity and during sweating
✅ Sensation-free
✅ 720 hours targeted pain relief
https://www.facebook.com/story.php?story_fbid=902558151905395&id=100064536555745&mibextid=qi2Omg&rdid=URPi9d5OMiBVi0WC
WOW!!!! Now Actipatch on the GYM's agenda!!! Nice Plug on GymProTips !!!!!!!!
ActiPatch® technology, your best ally
ActiPatch® is a therapeutic micro- device for personal use that works by means of electromagnetic fields that act at the source of pain. They stimulate cells that have been damaged and reduce inflammation of muscles and joints.
https://gymprotips.com/tips-to-speed-recovery-from-injury/
" RecoveryRx repairs and regenerates damaged cells by reducing pain and inflammation and accelerating blood flow. Whereas, TENS is only blocking pain signals and has no healing effect. The major difference between the two is that a TENS unit is a short term solution that “turns off” the pain signal but CANNOT perform the function of repairing damaged tissue like RecoveryRx. "
https://www.linkedin.com/posts/lauren-jarman-380a801a9_clinicallyproven-fdacleared-noninvasive-activity-7051200138563735553-Q9Zs
7 Well-Being Benefits of PEMF Therapy
https://www.samuelmaddockhealth.com/pemf/7-well-being-benefits-of-pemf-therapy
BioElectronics’ pulsed shortwave therapy device is effective for limb pain: study says
https://www.nsmedicaldevices.com/news/bioelectronics-pulsed-shortwave-therapy-device/
"Literally, there are so many benefits to a regular PEMF therapy session. Research by NASA and other bodies has found that PEMF therapy can deliver the following results:
Better circulation
Pain reduction
Improved muscle relaxation and performance
Decreased inflammation and swelling
Improved oxygenation in tissue
Enhanced cellular repair and recovery
Improved immune system
Better sleep "
https://higherdose.com/blogs/news/8-benefits-of-pemf-therapy?psafe_param=1&tw_source=google&tw_adid=634407957086&tw_campaign=18892036948&gad=1&gclid=CjwKCAjw44mlBhAQEiwAqP3eVqY1HlussPIpcLNFP0O10gqhWUrMI0VdqtspfI3FlKHqC0HkjB_OkBoCc08QAvD_BwE
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-------------------------------------------------------------------------------------------------
Actipatch ranked #1 in NASA Electromagnetic Pain Relief/Blocking: Feasibility Assessment !!!!!!!!
National Aeronautics and Space Administration
Lyndon B. Johnson Space Center
Houston, Texas 77058
( pages 14, 15 )........
Context/Background:
Astronauts use pharmaceuticals during spaceflight to manage acute and chronic pain, but use of analgesics will have drawbacks for exploration-class missions because the shelf life of these medications is limited, resupply will be curtailed, astronauts may develop tolerance and/or addiction to these medications, and side effects can include impairment of
cognitive abilities. Electromagnetic devices have been developed that treat pain terrestrially by affecting neuromodulation–dubbed “electroceuticals”, these devices have varied mechanisms of action that either stimulate or suppress neural activity in the central nervous system or peripheral nerves.
Objective/Purpose:
The available literature was reviewed and FDA-approved pain treatments (both pharmacological and non-pharmacological), as well as those currently under development, were assessed for their suitability for use in exploration class spaceflight missions.
Results:
An overwhelming majority of the literature focuses on the treatment of chronic rather than acute pain because it is assumed that acute pain only rarely fails to resolve and instead transitions into chronic pain when the central nervous system becomes hypersensitized. The available electromagnetic devices marketed for pain treatment have varying levels of
invasiveness, use different mechanisms of action, and have demonstrated varying efficacy when evaluated scientifically. A truly noninvasive, highly efficient device is desired for use during spaceflight. One portable, self-contained, FDA-approved device was identified that, from preliminarily assessment, best met these criteria; the device noninvasively applies pulsed
shortwave therapy (PSWT) to modify pain signals from peripheral nerves, however, the device has limited battery life and the effects are relatively non-selective in type of neural signal modified.
Ranking:
The treatment method ranked first in this review was pulsed
shortwave therapy (PSWT), a low-power RF (MHz range) transmitter operated adjacent to biological tissue at maximum output (saturation) to modulate peripheral nerve activity. ActiPatch is a very small wearable PSWT device that is FDA approved for “adjunctive treatment of musculoskeletal pain”
[Anwar-Deen 2020]. It is low cost, low power, and boasts 97% efficacy in reducing pain (85% over a 6-month period) [Staelin 2019]. The device can be secured to the body by physio tape and the area causing pain is bounded by the device’s ring. The device can be turned on and off, and the non-rechargeable battery is capable of 720 hours of operation
(one month continuous use). ActiPatch is sold OTC in local pharmacies for ~$30 [ActiPatch 2020].
Conclusions:
The information obtained in the execution of this review effort leads to 2 recommendations for forward work:
1. Tie into DoD and NIH research funding efforts to improve pain treatment: the NIH has a federal partners workgroup for their HEAL Initiative that could conceivably be joined by NASA, and the DoD CPMRP’s initial solicitation only recently completed so that program is young and potentially synergies could be identified with NASA.
2. Obtain an ActiPatch device for evaluation and determine whether it could be beneficial and adapted to spaceflight use.
https://ntrs.nasa.gov/api/citations/20205008893/downloads/2020ICA_Mullenax_report_24Sep20.pdf
___________________________________________________________
This is just a few FACTS to help with INTELLIGENT DD and to INVEST in BIEL, which, i/we agree with this post worth a reasonable investment:
(https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172266874;; )
INTRODUCING
RecoveryRx Veterinary
Drug-Free Pain Relief Device
For Indoor and Outdoor Pets
https://rrxvet.carrd.co/
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Vet Recovery RX
"An innovation in drug-free pain and edema management. RecoveryRx is a class II, USA FDA-cleared, non-thermal shortwave therapy device which utilizes radio-frequency electromagnetic energy to modulate nerve activity"
https://vetphysiodevon.com/vet-recoverry
rx#:~:text=An%20innovation%20in%20drug%2Dfree,energy%20to%20modulate%20nerve%20activity
Alpha Animal Rehab and Fitness is at Alpha Animal Rehab and Fitness.
Exciting news at #AARF—we have two new products to support your pup’s health and recovery: RecoveryRX and YuMove! 🐾 RecoveryRX is a wearable device that uses low-level electromagnetic therapy to help reduce pain and inflammation, perfect for dogs recovering from surgery or dealing with chronic conditions.
https://www.facebook.com/story.php?story_fbid=463227680005342&id=100089543403668&mibextid=xfxF2i&rdid=KBLw46cEZ1egeIst
PEMF Ring is Saving a 14 Year Old Labrador
https://therapyproducts.net/pemf-ring-is-saving-a-14-year-old-labrador/
Alpha Animal Rehabilitation and Fitness | NJ
Pet Service
Certified Canine Rehab Therapists helping pets with conditions/injuries/post surgery to manage pain and recover holistically through Physical Therapy
316 3rd Ave, Alpha, New Jersey 08865
https://investorshangout.com/images/MYImages/519436370_Screenshot_27-8-2024_7119_www.instagram.com.jpeg
A SDVOSB Owned Exclusive Provider of RecoveryRx for VA ( Veterans ) Hospitals!!!
https://veteranrecovery.org/
Veterans, connect with us to learn more about RecoveryRx®
New PAIN RELIEF TECHNOLOGY at the push of a button!!!
https://kellycovemobility.com/rrx/
BIEL$$$
RecoveryRX Major General Livingston, a Medal of Honor recipient, who had 6 operations for back, does a fantastic job describing his experience with RecoveryRx Pain Relief!!!!!
https://youtu.be/jljs7QPX7KE
"As the sole UK and European distributor of Recovery RX Veterinary, Tanya Sprunks offers advanced long-lasting pain relief for pets using Electromagnetic Pulse Therapy. She operates several successful clinics across Devon, focusing on Veterinary Physiotherapy."
https://www.glebevets.co.uk/services/physiotherapy/
___________________________________________________________
Skymedicalsupply
•skymedicalsupply's profile picture
Introducing the EME BACK WRAP with ActiPatch® Technology, a revolutionary pain relief solution for your back. This innovative wrap utilizes ActiPatch® technology, clinically proven to alleviate pain by regulating the activity of sensitized nerves and reducing abnormal pain signaling. With its ability to deliver 1,000 sensation-free electromagnetic pulses per second, this wrap offers effective relief for up to 720 hours.
https://www.instagram.com/skymedicalsupply/p/C6J0wXQCGLF/
___________________________________________________________
Welcome to the largest
health and beauty store in Europe! PromoFarma is the marketplace which groups the catalogues from more than 1.000 pharmacies and other sellers into one single website, selects the basket of products at the best price, collects the order from the selected pharmacies and delivers it wherever you want.
ActiPatch effective knee-pain relief !!!!!!!!
https://www.promofarma.com/en/actipatch-effective-knee-pain-relief-1pc/p-552091
_________________________________________________________
Accelerated recovery of post-operative dental implant patients using drug-free RecoveryRx.
Read the paper here:
https://lnkd.in/daQ4GRa
#painrelief #neuromodulation #fdacleared #drugfree #clinicallyproven #painmanagement #oralsurgery #dentalimplants #postsurgical
https://www.linkedin.com/posts/bioelectronics-corporation_painrelief-neuromodulation-fdacleared-activity-6778677760979152896-XQZ1
BioElectronics’ pulsed shortwave therapy device is effective for limb pain: study says
https://www.nsmedicaldevices.com/news/bioelectronics-pulsed-shortwave-therapy-device/
__________________________________________________________________
Chairman Updates Investors
Outlines Sales Activities, Clinical Trials, and a potential legal Action Against MundiPharma
FREDERICK, MD. October 16, 2024 -- (GLOBE NEWSWIRE) -- via NewMediaWire
https://www.facebook.com/BioElectronics/
BioElectronics Chairman Updates Investors
Thu, February 15, 2024 at 9:00 AM EST
https://finance.yahoo.com/news/bioelectronics-chairman-updates-investors-140000529.html
______________________________________________________________
Voices for Non-Opioid Choices Coalition Applauds Introduction of Alternatives to PAIN Act in Senate
https://www.prnewswire.com/news-releases/voices-for-non-opioid-choices-coalition-applauds-introduction-of-alternatives-to-pain-act-in-senate-302076547.html
____________________________________________________________
CHEMIST4u ( UK )
ActiPatch Muscle and Joint Pain Therapy Devices
https://www.chemist-4-u.com/brands/actipatch?fbclid
=IwAR21Sy7YpQYVw-otDE2ah9aPf-DNslt0jUw4xJMFcKxAXRyo_JkWNQ7TcYI
____________________________________________
ActiPatch is the drug-free solution for pain. It interrupts abnormal pain signaling in the nerves. You won't feel anything but relief. $$$ BACK GUARANTEE USA:
http://actipatch.com 📷
No More Dangerous, Addictive or Expensive Drugs.
https://twitter.com/ActiPatch/status/1752421581769363689?s=20
___________________________________________________________________
ActiPatch®
@ActiPatch
ActiPatch reaches deep into the painful area to provide real relief at the source. Can be used 24/7. You won't feel anything but PAIN RELIEF.
$$$ BACK GUARANTEE OFFER USA:
http://actipatch.com 📷 #neckpainrelief #techneckrelief #painrelief #neckarthritisrelief #neckpain
https://twitter.com/ActiPatch/status/1745131740358729994?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1745131740358729994%7Ctwgr%5E811275876d36002daf58d004f9820350cd7adb08%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Finvestorshub.advfn.com%2Fboards%2Fread_msg.aspx%3Fmessage_id%3D173613351
ITS coming to BIEL $$$$$$$$$$$$$$$$$$$!!!!!!!!!!!!!!!!!!!!!!!!
11/20/2023
Washington State poised to extend coverage for SCS
https://www.neuromodulation.org/news/washington-state-poised-to-extend-coverage-for-scs
________________________________________________________________
ActiPatch SA
February, 6 at 1:35 Am
Struggling with chronic pain? 🤕 ActiPatch® pain-relief device is clinically proven to relieve muscle and joint pain!¹?³
✅ Ideal for arthritis, back pain, knee pain, fibromyalgia, and more.²
🔍 Targeted, long-lasting pain relief in just 2-3 hours.¹
🔋 Lasts up to 720 hours for continuous comfort.
🚀 Small & lightweight.¹ Say goodbye to bulky equipment!
Get back to feeling your best with ActiPatch®, available at Dis-Chem Pharmacies, Clicks and leading pharmacies nationwide.
#ActiPatch #DrugFree #PainRelief #PainManagement #ChronicPainManagement #JointPainRelief #SportsInjuryRelief#BackPainRelief
https://www.facebook.com/watch/?v=1124676815379216
__________________________________________________________________
NANS Advocacy Results in HCSC Adding Closed-Loop Spinal Cord Stimulation to Coverage!!
https://www.neuromodulation.org/news/closed-loop-04172023
_______________________________________________________________
ActiPatch®
@ActiPatch
Get the sleep you deserve with relief from ActiPatch! ActiPatch doesn't just put a band-aid on pain. It dives deep with its Pulsed Shortwave Therapy & takes on pain at its root for sustained relief! Order at:
http://actipatch.com FREE SHIPPING. #painmanagement #painfreesleep
https://twitter.com/ActiPatch/status/1737209416749887575?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1737209416749887575%7Ctwgr%5E811275876d36002daf58d004f9820350cd7adb08%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Finvestorshub.advfn.com%2Fboards%2Fread_msg.aspx%3Fmessage_id%3D173613351
___________________________________________________________
Chronic Pain, Fibromyalgia and Plantar Fasciitis Help --- ACTIPATCH!!!
https://www.facebook.com/groups/1795257327156301/?multi_permalinks=7709195185762456
BioElectronics’ pulsed shortwave therapy device is effective for limb pain: study says
https://www.nsmedicaldevices.com/news/bioelectronics-pulsed-shortwave-therapy-device/
_____________________________________________________________
ActiPatch SA
If tennis injuries are following you off the court, ActiPatch® can help lessen your downtime by serving up clinically proven joint and muscle pain relief!²,³
🎾 Drug free¹
🎾 Can be worn 24/7, even during physical activity and sweating¹
https://www.facebook.com/share/v/jdHfKoc7x7dB...tid=CYgPv5
Old sports injury trying to bench you from the summer fun? 🌞🌊 Get back in there with ActiPatch® on your team! 🌟
✅ Pain relief can be felt after just 2-3 hours
✅ Safe to use during regular physical activity and during sweating
✅ Sensation-free
✅ 720 hours targeted pain relief
https://www.facebook.com/story.php?story_fbid=902558151905395&id=100064536555745&mibextid=qi2Omg&rdid=URPi9d5OMiBVi0WC
WOW!!!! Now Actipatch on the GYM's agenda!!! Nice Plug on GymProTips !!!!!!!!
ActiPatch® technology, your best ally
ActiPatch® is a therapeutic micro- device for personal use that works by means of electromagnetic fields that act at the source of pain. They stimulate cells that have been damaged and reduce inflammation of muscles and joints.
https://gymprotips.com/tips-to-speed-recovery-from-injury/
ActiPatch SA
tnepdosrSo810ii
There's a champion inside all of us – don’t let chronic pain hold you back! If life is the #2024Olympics, then ActiPatch® is your #1 supporter. 💪
https://www.facebook.com/watch/?mibextid=oFDknk&v=1038405881014609&rdid=FMmcKKO2DsmHYISt
You might have thought chronic pain would be with you for life, but now there's something that can help. 🌟 Meet ActiPatch®: pain relief
https://www.facebook.com/watch/?mibextid=CYgPv5&v=909395761002533&rdid=cqiPcvFNpcuizRNh
SAI, Airway, KT, have all renewed their 'FDA Establishment Registration' to sell ActiPatch for 2025
Name .......................................................................... Reg # ... Year
AIRWAY SURGICAL APPLIANCES LTD. CANADA .... 9611956 2025
KT Health, LLC UT/USA .........................................3007282994 2025
SURGICAL APPLIANCE INDUSTRIES, INC. OH/USA 1511629 2025
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm ("PQY" product code)
_________________________________________________________
PEMF Alzheimer’s Treatment Pilot Underway at Hackensack University Medical Center
https://www.hackensackmeridianhealth.org/en/info/geriatrics/evoke-trial
BioElectronics’ pulsed shortwave therapy device is effective for limb pain: study says
https://www.nsmedicaldevices.com/news/bioelectronics-pulsed-shortwave-therapy-device/
----------------------------------------------------------------------------------------
BioElectronics Corporation’s Post
View organization page for BioElectronics Corporation
BioElectronics Corporation
3,331 followers
Both NSAID therapy and neuromodulation therapy using PSWT resulted in statistically and clinically important reductions in pain level and improvement in functionality associated with cervical osteoarthritis, when used for 4 weeks. However, the PSWT intervention demonstrated superior improvements in all outcome measures when compared to the etoricoxib therapy arm, including patient satisfaction rating and decreased use of rescue pain medication. These results suggest that neuromodulation using PSWT may be a superior pain treatment option, when compared to COX-2 NSAIDS for neck osteoarthritis, and as well, represents a non-invasive, non-pharmacologic treatment option.
Product samples are available to licensed medical care providers in the USA. Request via email - info[ @newbie00
https://www.linkedin.com/posts/bioelectronics-corporation_pulsed-shortwave-therapy-in-cervical-osteoarthritis-activity-7138985310968795136-SRFJ
https://link.springer.com/article/10.1007/s42399-020-00652-y
---------------------------------------------------------------------------------------------------
New product added
https://actipatch.com/buy-1
BioElectronics’ pulsed shortwave therapy device
is effective for limb pain: study says
https://www.nsmedicaldevices.com/news/bioelectronics-pulsed-shortwave-therapy-device/
MD Medical
MD Medical is the fastest growing medical company in kuwait.
SIster Company @socheck_kuwait
Kuwait, Hawally Governorate, Salmiya, Block 2, Abdullah Bin Masoud Street, Al-Ras Tower, Floor 3, Office No.B3, Kuwait City 13091
https://www.instagram.com/mdmedicalco/
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-------------------------------------------------------------------------------------------------
Top5-USA.co
Top 5 Actipatch In The US
https://www.top5-usa.com/actipatch
------------------------------------------------------------------------------------------------------
RecoveryRX
BOSTON ORTHOPEDIC & RESPIRATORY EQUIPMENT, LLC.
https://www.bostonorthoresp.com/214-4_p_10155.html?referrer=rss
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-----------------------------------------------------------------------------------------------------------
This is just a few FACTS to help with INTELLIGENT DD and to INVEST in BIEL, which, i/we agree with this post worth a reasonable investment:
(https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172266874;; )
"RecoveryRx repairs and regenerates damaged cells by reducing pain and inflammation and accelerating blood flow. Whereas, TENS is only blocking pain signals and has no healing effect. The major difference between the two is that a TENS unit is a short term solution that “turns off” the pain signal but CANNOT perform the function of repairing damaged tissue like RecoveryRx."
https://www.linkedin.com/posts/lauren-jarman-380a801a9_clinicallyproven-fdacleared-noninvasive-activity-7051200138563735553-Q9Zs
A SDVOSB Owned Exclusive Provider of RecoveryRx for VA ( Veterans ) Hospitals!!!!
https://veteranrecovery.org/
Veterans, connect with us to learn more about RecoveryRx®
New PAIN RELIEF TECHNOLOGY at the push of a button!!!
https://kellycovemobility.com/rrx/
BIEL$$$
RecoveryRX Major General Livingston, a Medal of Honor recipient, who had 6 operations for back, does a fantastic job describing his experience with RecoveryRx Pain Relief!!!!!
https://youtu.be/jljs7QPX7KE
"Literally, there are so many benefits to a regular PEMF therapy session. Research by NASA and other bodies has found that PEMF therapy can deliver the following results:
Better circulation
Pain reduction
Improved muscle relaxation and performance
Decreased inflammation and swelling
Improved oxygenation in tissue
Enhanced cellular repair and recovery
Improved immune system
Better sleep "
https://higherdose.com/blogs/news/8-benefits-of-pemf-therapy?psafe_param=1&tw_source=google&tw_adid=634407957086&tw_campaign=18892036948&gad=1&gclid=CjwKCAjw44mlBhAQEiwAqP3eVqY1HlussPIpcLNFP0O10gqhWUrMI0VdqtspfI3FlKHqC0HkjB_OkBoCc08QAvD_BwE
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-------------------------------------------------------------------------------------------
Watch till the end!
https://www.instagram.com/reel/Cvq8j0bILP4/?igshid=MzRlODBiNWFlZA==
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-------------------------------------------------------------------------------------
This is just a few FACTS to help with INTELLIGENT DD and to INVEST in BIEL, which, i/we agree with this post worth a reasonable investment:
(https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172266874;; )
INTRODUCING
RecoveryRx Veterinary
Drug-Free Pain Relief Device
For Indoor and Outdoor Pets
https://rrxvet.carrd.co/
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Vet Recovery RX
"An innovation in drug-free pain and edema management. RecoveryRx is a class II, USA FDA-cleared, non-thermal shortwave therapy device which utilizes radio-frequency electromagnetic energy to modulate nerve activity"
https://vetphysiodevon.com/vet-recovery-rx#:~:text=An%20innovation%20in%20drug%2Dfree,energy%20to%20modulate%20nerve%20activity
Alpha Animal Rehab and Fitness is at Alpha Animal Rehab and Fitness.
Exciting news at #AARF—we have two new products to support your pup’s health and recovery: RecoveryRX and YuMove! 🐾 RecoveryRX is a wearable device that uses low-level electromagnetic therapy to help reduce pain and inflammation, perfect for dogs recovering from surgery or dealing with chronic conditions.
https://www.facebook.com/story.php?story_fbid=463227680005342&id=100089543403668&mibextid=xfxF2i&rdid=KBLw46cEZ1egeIst
PEMF Ring is Saving a 14 Year Old Labrador
https://therapyproducts.net/pemf-ring-is-saving-a-14-year-old-labrador/
Alpha Animal Rehabilitation and Fitness | NJ
Pet Service
Certified Canine Rehab Therapists helping pets with conditions/injuries/post surgery to manage pain and recover holistically through Physical Therapy
316 3rd Ave, Alpha, New Jersey 08865
https://investorshangout.com/images/MYImages/519436370_Screenshot_27-8-2024_7119_www.instagram.com.jpeg
"As the sole UK and European distributor of Recovery RX Veterinary, Tanya Sprunks offers advanced long-lasting pain relief for pets using Electromagnetic Pulse Therapy. She operates several successful clinics across Devon, focusing on Veterinary Physiotherapy."
https://www.glebevets.co.uk/services/physiotherapy/
----------------------------------------------------------------------------------------------------------
Old sports injury trying to bench you from the summer fun? 🌞🌊 Get back in there with ActiPatch® on your team! 🌟
✅ Pain relief can be felt after just 2-3 hours
✅ Safe to use during regular physical activity and during sweating
✅ Sensation-free
✅ 720 hours targeted pain relief
https://www.facebook.com/story.php?story_fbid=902558151905395&id=100064536555745&mibextid=qi2Omg&rdid=URPi9d5OMiBVi0WC
Once, pay ATTENTION Everyone -- NOT if, imo, NHL, NFL, NBA, WBA, MLB, PGA, Lacrosse, etc...... adopts Actipatch as a must protocol, after all those HITS, CHECKS, TRIPS, LIGAMENT PULLS/RIPS, etc.......Possibilities are ENDLESS !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
WOW!!!! Now Actipatch on the GYM's agenda!!! Nice Plug on GymProTips !!!!!!!!
ActiPatch® technology, your best ally
ActiPatch® is a therapeutic micro- device for personal use that works by means of electromagnetic fields that act at the source of pain. They stimulate cells that have been damaged and reduce inflammation of muscles and joints.
https://gymprotips.com/tips-to-speed-recovery-from-injury/
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
----------------------------------------------------------------------------------------------------
From 3331:
WHICH CATALYST WILL BE FIRST?
:
1000 Veterinarian Clinics (USA):
Conservatively assume each office orders 10/mo. @ $100 each for BIEL (Vet sells for $200, a bargain compared to Assisi):
1000 x 100 x 10 x 12 = $12,000,000 rev/year.
100 VA Hospitals:
Conservatively assume each hospital orders 100 RecoveryRx per month ($100 each for BIEL):
100 x 100 x 100 x 12 = $12,000,000 rev/year.
Using profit = $20 mil and P/E = 100:
PPS = .08!
Additional revenue could be generated from new FDA clearances, vagus nerve patent, NPA, UK/Australia contract rumor, etc. Initiating a stock buyback program after all of the loans are paid off would propel the pps much higher (pps = .25 to $1?).
ADDITIONAL CATALYST:
Here are some additional numbers using Taiwan as a catalyst, using beacham's conservative numbers of 1% market penetration w/$10 profit/unit yields $43 million revenue:
$3 million = break even, cash flow positive: pps = .01.
Each additional $2.5 million/year should result in an additional .01 increase in pps (P/E = 100).
For revenue = $43 million, profit = $40 million (and applying the tax loss carryforward), resulting pps =
.16 (P/E = 100)
.32 (P/E = 200)
.48 (P/E = 300)
However, there are several factors that indicate this estimate might be extremely conservative, such as:
1) Taiwan appears to be using the RecoveryRx (requires doctor approval) version of Actipatch (OTC), which would have a higher profit than $10/unit.
2) market penetration will likely be higher than 1%.
Therefore, a case could be made for increasing the above estimates 10-fold or more (although tax would then need to be factored in). Now factor in the VA, veterinary, and other rumored contracts (if they materialize), and you're taking some serious money!
ANOTHER BIEL VALUATION MEASURE: QUBT hit $27/share recently, even though their revenue last year ($358k) was half that of BIEL ($715k). Accounting for the difference in outstanding shares (25 bil vs 100 mil), BIEL pps = .10 is the equivalent valuation to QUBT = $27/share.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175566191
3331
1 day ago
BIEL + Viant + VLMS: Smart Relief Alliance
Transforming Non-Opioid Pain Relief into Scalable Digital Health
Executive Summary
ActiPatch by BioElectronics Corp is a clinically validated, FDA-cleared wearable using pulsed electromagnetic field (PEMF) therapy for chronic pain relief. In partnership with Viant Medical and VLMS Global Healthcare, ActiPatch will be scaled, digitally enhanced, and positioned for insurance reimbursement—creating an end-to-end solution for non-opioid pain management.
Integrated Value Proposition
This collaboration merges:
1) BIEL's proprietary PEMF tech and clinical data
2) Viant's expertise in smart device engineering, mobile integration, and manufacturing scalability
3) VLMS’s healthcare reimbursement infrastructure, coding expertise, and market entry support
Together, they’ll deliver a connected, AI-powered therapy platform that meets regulatory standards and market demand for low-cost, non-pharma alternatives.
Product & Platform Snapshot
ActiPatch and RecoveryRx devices are designed for chronic pain such as back, joint, and post-operative discomfort. They are safe for long-term use, with no drug interactions and FDA clearance for over-the-counter availability. The new connected platform will feature mobile app integration, sensors, HIPAA-compliant data tracking, and remote care capabilities.
Business Model
Revenue will be generated through:
1) Device sales ranging from $50–$100, bundled with app access
2) Monthly subscriptions ($5–$10) for AI dashboards and clinical tools
3) Clinical bundles for post-op and rehabilitation use cases
4) Licensing of de-identified health data for pharma and academic research
5) Strategic B2B partnerships with hospitals, retail chains, and telehealth networks
Financial & Market Forecast
Year 1: 100,000 users and an average revenue of $40 per user, total revenue is projected at $4 million.
Year 2: 500,000 users at $40 per user yields $20 million.
Year 3: 1 million users at $40 per user drives $40 million in revenue.
The projected device profit margin is 80%, or $40 per unit sold. Growth will be supported by low customer acquisition cost through chronic pain communities and retail channels, while long-term value is increased by subscription, device upgrades, and recurring care models.
Market Opportunity
The U.S. chronic pain market is valued at $80.92 billion in 2025 and expected to grow to $96.53 billion by 2030. Globally, the PEMF therapy device market is forecasted to expand from $755.82 million in 2024 to $1.19 billion in 2033—driven by remote therapy demand, aging populations, and opioid-free treatment trends. Meanwhile, digital health apps are growing more than 18% annually, and the bioelectronic wearables space is expected to hit $18 billion by 2028.
Strategic Contributions
BioElectronics Corp (BIEL)
Owns the IP and PEMF technology
Provides clinical studies and FDA clearances
Maintains regulatory leadership for OTC access
Viant Medical
Designs and builds connected smart devices
Leads firmware and app development
Ensures compliance, scalability, and optimized form factor
Bridges hardware development and BIEL’s legacy leadership through Dr. Sree Koneru
VLMS Global Healthcare
Crafts CMS coding strategy for reimbursement
Operates billing, claims management, and provider onboarding
Executes go-to-market strategy via Keith Nalepka’s retail expertise and investor relations
Supplies data infrastructure and facilitates hospital/insurance partnerships
Competitive Differentiation
This alliance brings the only FDA-cleared OTC PEMF wearables with true clinical backing to market as connected, AI-enabled solutions. With physician integration and smart analytics, it delivers precision care and positions itself as a scalable, credible alternative to opioids—ready to align with fitness trackers, remote care platforms, and institutional channels.
APPLE + BIEL = BIELIONAIRES!
Integrating an intelligent ActiPatch/RecoveryRx system with a device like the Apple Watch, or similar smartwatches (Google Pixel Watch, Samsung Galaxy Watch, Garmin, Fitbit, etc.), is not only feasible but would be a highly effective way to achieve the "intelligent, adaptive pain management system" vision.
Here's how this integration would work and why it's a strong approach:
Leveraging the Smartwatch as the Data Hub and AI Processor (or Gateway):
Instead of building all the sensors and processing power directly into the tiny, disposable ActiPatch, the smartwatch can serve as the central brain and data collector.
1. Sensor Data Acquisition:
* Existing Smartwatch Sensors: Modern smartwatches already possess many of the physiological sensors needed for comprehensive pain assessment:
* Heart Rate (HR) & Heart Rate Variability (HRV): Excellent indicators of stress, pain, and recovery.
* Activity Tracking (Accelerometer, Gyroscope): Detects movement, sleep patterns, and activity levels, crucial for understanding pain context and recovery progress.
* Skin Temperature: Apple Watch Series 8 and newer, and all Ultra models, have wrist temperature sensing, which can indicate inflammation or illness.
* Sleep Tracking: Provides insights into sleep quality, which is vital for pain management and recovery.
* Blood Oxygen (SpO2): While less directly tied to pain, it's another overall health metric.
* ECG (Electrocardiogram): Can detect irregular heart rhythms, which can be linked to stress or other underlying conditions.
* ActiPatch with Minimal Sensors: The ActiPatch itself would primarily need to focus on its core function:
* Bluetooth Low Energy (BLE) Module: This is critical for communicating with the smartwatch. The ActiPatch would transmit its operational status (e.g., "on/off," "battery level") and potentially receive new PEMF parameters from the smartwatch.
* Basic Confirmation Sensor (Optional but helpful): A simple contact sensor could confirm the patch is properly applied to the skin, preventing wasted therapy.
* Modulatable PEMF Generator: The most important internal modification would be to allow the ActiPatch to receive commands from the smartwatch to dynamically adjust its PEMF output (frequency, intensity, pulse duration). This means the ActiPatch wouldn't just be "on" or "off" at a fixed setting, but could deliver a nuanced, AI-guided therapy.
2. Data Flow and AI Processing:
* Smartwatch to iPhone (or Android Phone): Health data from the Apple Watch (or other smartwatches) is already seamlessly synced to the Health app on the user's iPhone.
* Dedicated ActiPatch/RecoveryRx App: A dedicated app would be developed for the iPhone (and potentially a companion Watch app for simpler interactions). This app would:
* Access HealthKit Data: Through Apple's HealthKit framework, the app would securely access the relevant physiological and activity data collected by the Apple Watch (with user permission).
* Integrate User Input: Allow users to log subjective pain levels, specific activities that trigger pain, medication intake, and other qualitative data.
* Host the AI Engine: The AI algorithms (Machine Learning, Reinforcement Learning) would run within this app or leverage cloud computing if more intensive processing is required. This AI would:
* Correlate Data: Analyze the Watch's objective sensor data with the user's subjective pain input.
* Identify Pain Patterns: Learn what physiological and activity patterns correlate with pain onset, increase, or decrease for that specific individual.
* Generate Adaptive PEMF Prescriptions: Based on the AI's real-time assessment of pain and recovery, it would determine the optimal PEMF settings.
* Send Commands to ActiPatch: Via BLE, the app would then send commands to the modified ActiPatch, instructing it to adjust its PEMF parameters.
3. User Experience and Feedback Loop:
* Smartwatch Notifications: The Apple Watch could deliver subtle haptic notifications or on-screen alerts, for example:
* "Pain spike detected: ActiPatch intensity increased."
* "Consistent use is improving recovery. Keep it up!"
* "Time to apply your ActiPatch for optimal overnight recovery."
* Watch App Interface: A simplified Watch app could allow users to quickly:
* See current pain status.
* Manually trigger or stop therapy.
* Log quick pain severity ratings.
* iPhone App Dashboard: The main iPhone app would provide a rich dashboard with:
* Historical pain trends vs. therapy application.
* Insights into correlations (e.g., "Your pain tends to be lower after consistent therapy and X hours of sleep.").
* Progress reports shared with healthcare providers (with consent).
Why this integration is powerful:
* Reduced Hardware Complexity for ActiPatch: The ActiPatch remains small and lightweight, as it doesn't need to contain a full suite of sensors or heavy processing. This keeps manufacturing costs down and maintains its comfortable wearability.
* Leverages Existing Ecosystem: Taps into the vast user base and mature health tracking capabilities of smartwatches and smartphone health platforms (like Apple HealthKit).
* Rich Data Stream: Smartwatches provide a continuous and diverse stream of physiological and activity data, which is crucial for training and operating sophisticated AI models for personalized pain management.
* User Familiarity: Users are already accustomed to interacting with smartwatches and health apps, reducing the learning curve.
* Continuous Monitoring: Unlike a device that only measures when you activate it, the smartwatch provides 24/7 background monitoring, allowing the AI to gather comprehensive context.
In essence, the Apple Watch (or similar) would act as the "eyes and ears" and much of the "brain" for the ActiPatch system, allowing the ActiPatch to become a highly responsive and personalized "treatment delivery arm."
BIEL GONNA RUN LIKE 2021!
Everything is falling into place just like 2021. A new distribution partner for the USA will be announced soon (replacing the KT deal from 2021). OTC bull market runs are fueled by the Fed cutting interest rates, and the Fed is now forecast to cut several times this year. Falling interest rates indicate a more accommodative money policy which makes investors more interested in the higher risk/higher reward stocks found on the OTC. The last time this happened, BIEL ran more than 1,600% to .0088. The previous BIEL runs coincided with similar OTC bull markets in 2017, 2014 and 2009.
The technical indicators come first - the Golden Cross and the Blue Sky Breakout. Then the fundamentals kick in (Taiwan, VA, Veterinary, New Zealand...). BIEL is a Reddit investors dream. Once they become aware of BIEL (via the financial press), the pps will rocket, product sales will soar, and we'll be celebrating like 2021!
BIEL COULD HIT COPPER IN THE "BLINK OF AN EYE"!
The first catalyst will likely be the announcement of a new partner for the USA (GOOD RIDDANCE KT), which could come any day! The key statement from the annual report is "The Company has focused attention on seeking a distribution and licensing partner for the OTC US market". If investors value this partnership at $300k (and add it to the $496k of mostly international revenue reported for 2024), the pps gets out of the trips. If the investor valuation is $1 million, then the pps hits COPPER! The last time this happened (KT deal in 2021), BIEL soared 1,600%.
BIEL GOES VIRAL AT PPS = .003!
Market cap = $75 million at pps = .003, which would generate massive press (free marketing/advertising) in the news and financial media when they report that the pps increase is better than the gains in Amazon and Apple (3,000% over the past 10 years). It would solve all of BIEL's problems and create numerous opportunities for the company. The Reddit crowd would be all over it (generating massive free online marketing/advertising). If the company then declares profits would be used for a share buyback program (after paying off the loans), the pps would soar ($1+) and the rise would be sustained.
BIEL - SIMPLE, CLEAR PATH TO SUCCESS
BIEL is undervalued at just $5 million with $496,000 in revenue (2024), compared to companies that boast billion-dollar valuations despite generating less revenue. For instance, QUBT holds a $2.3 billion market cap on just $373,000 in revenue. As awareness grows around the advantages of PSWT/PEMF technology and the vast multi-billion-dollar, drug-free pain management market—where FDA-cleared ActiPatch, RecoveryRx, and RecoveryRx Veterinary products are poised to lead—BIEL's potential for massive growth becomes undeniable.
In Q3 2021, BIEL achieved profitability with $22,381 in earnings on $414,700 in revenue, including over $100,000 in COVID relief funds. With its exceptionally low operating costs and efficient business model, profitability is within reach. A $1.5 million annual revenue—or a $400,000 quarter—could be the tipping point, potentially driving the stock price to $0.01 and increasing by $0.01 for every additional $2.5 million in annual revenue (P/E = 100). Moreover, the company's $40 million tax-loss carryforward ensures that the first $40 million in profits remain tax-free, accelerating the road to sustained profitability. If management hints at profitability in Q1 2025 or suggests Q2 will be profitable, investor confidence will grow and the PPS would hit COPPER, solving key challenges, and unlocking new opportunities.
BIEL IS THE NEXT BITCOIN (ROI)!
The Bitcoin return on Investment (ROI) is about 40,000% over the past 10 years. BIEL will go viral at PPS = .003, as it would generate massive press (free marketing/advertising) in the news and financial media when they report that the PPS increase is better than the gains in Amazon and Apple (3,000% over the past 10 years). It would solve all of BIEL's problems and create enormous opportunities for the company. The Reddit crowd would be all over it - generating a Bitcoin like frenzy and more free marketing/advertising - which could catapult the PPS to .04 (40,000% ROI on my .0001 shares)!
OTC stocks are heating up, as they always do when a bull market matures. While most trip zero stocks are scams or shells, BIEL is the ONLY trip zero stock that has been in business for over 20 years (without ever doing a reverse split) and has a real product (with five FDA clearances) that gets rave reviews!!!
BIEL’s GROWTH PATH AND MILESTONE TARGETS
1️⃣ Move out of trips when hints of a major deal emerge—triggering technical indicators like the Golden Cross (0.0004) and Blue Sky Breakout (0.0005).
2️⃣ PPS = 0.003: A 3,000% surge, surpassing Apple & Amazon’s 10-year growth rate, following a U.S. distributor announcement—then going viral.
3️⃣ PPS = 0.01: A 10,000% increase, a $400k revenue quarter (or hint of) should do it!
4️⃣ PPS = 0.04: A 40,000% surge, backed by $10M profit, akin to Bitcoin’s performance over the past 10 years.
5️⃣ PPS = 0.10: A 100,000% increase, requires $25M profit (P/E = 100).
The Easiest, Fastest & Most Likely Path to Success
🔹 Generate a $400K revenue quarter—or persuade investors it’s imminent—reaching copper.
🔹 Achieve a $1.5M annual revenue—or convince markets it’s incoming.
🔹 Management hints profitability for Q1 or Q2 2025, reinforcing investor confidence.
🔹 Investors value the new U.S. partnership at $300K, bringing PPS above 0.001—or at $1M, launching it to copper.
BIEL’s Prospectus & Long-Term Outlook
BIEL’s lean OEM business model is positioning the company for rapid profitability. Considering investor projections:
1️⃣ $800K annual revenue: A significant revenue jump from recent years, moving PPS beyond trips.
2️⃣ $1.5M revenue or a $400K quarter: Likely to secure cash flow positivity & profitability, boosting PPS to copper.
3️⃣ 1,000,000%+ upside potential is unmatched by any other stock on the market.
4️⃣ $40M tax-loss carryforward—meaning the first $40M in profits will be tax-free, accelerating net earnings growth.
Final Outlook: BIEL Could Be the Next Viral Phenomenon
At PPS = 0.003, BIEL could dominate headlines—its market cap hitting $75M alongside comparisons to Apple and Amazon’s long-term gains. Investor enthusiasm could fuel a run toward $1+, sustained by a share buyback program (after the loans are paid off).
If momentum continues:
✅ PPS = 0.10: 100,000%, requires $25M profit (P/E = 100—amplified by tax advantages).
✅ PPS = $1: 1,000,000% increase, sustained by a share buyback program (after the loans are paid off).
TURN $1 INTO $1,000,000 - BIEL IS IDEAL FOR A REDDIT SURGE
The 1,000,000%+ upside potential is unmatched by any other stock on the market. BIEL could hit copper in the blink of an eye - a $400k revenue quarter (or hint of) should do it!
With approximately 15 billion BIEL shares locked in the hands of dedicated long-term investors—who, like me, may never sell—the available float shrinks to around 10 billion shares. That presents a unique opportunity for accumulation on the open market. In fact, it would take a relatively modest sum—just $2,000,000 at the current $0.0002 per share (1,000 Redditers investing $2,000)—to gain significant control over BIEL's available shares.
Investor sentiment surrounding BIEL is strong, with thousands closely watching its price action. The moment the PPS ticks upward, a surge of buyers is likely to follow. Given that the majority of outstanding shares are held tightly, the price could skyrocket upon ignition. The classic supply-demand imbalance favors an explosive move (SQUEEZE!), as demand outstrips the limited availability of shares.
The price appreciation wouldn't wait for full accumulation—rather, it would likely rise steadily as the 10 billion shares are scooped up. The real question is how high it could go. With BIEL catching the attention of retail investors—including the Reddit crowd—a substantial rally isn't out of the question.
We've seen similar explosive moves in stocks like GameStop (GME), where retail enthusiasm and strategic buying pressure drove the price to unprecedented highs.
With rising revenues, especially a $400,000 quarter (or hints of) that would likely produce a profit, the PPS would soar. A move to $0.10? Certainly within reach.
BIEL is positioned for explosive growth. The key lies in executing strategic partnerships, revenue milestones, and market positioning—paving the way for one of the biggest potential stock surges in recent history. At PPS = $10 (after the share buyback), every $1 invested in .0001 shares will be worth $1,000,000!
VETERANS ADMINISTRATION (HUGE)!
RecoveryRx now available through prosthetics for pain management, ortho, PT (courtesty of edbi):
VA providers now have access to recently FDA-approved non-opioid, non-invasive pain management device through RecoveryRx. RecoveryRx produces an electromagnetic field at the point of pain that changes how cells communicate pain. Research, technical information and studies available at www.RecoveryRx.co. It is an amazing device, unlike TENS units, RecoveryRx reduces pain without any kind of electrical stimulation feeling for the veteran. The antenna lasts 30 days, all Ortho, pain management, and PT providers can work through prosthetics (RecoveryRx is on the FSS) to get these on their patients for feedback and widespread use at the VA.
Courtesy of Av8tor65:
Just a quick note to share that the Central Texas VA Hospital is now prescribing the RecoveryRx device. Earlier today, I gave a Recovery Rx device to a co-worker who was heading to a pain management appointment at the VA and encouraged him to take the device with him to show his doctor. Turns out, the doctor was already familiar with RecoveryRx and is actively prescribing it. The physician agreed to prescribe one for my co-worker as well, who, notably, is a Purple Heart recipient. Great to see continued momentum and recognition for this technology in veteran care settings. Millions of devices could be distributed throughout the VA network. I will be next......
CORNERING THE BIEL MARKET - A STRATEGIC PERSPECTIVE:
In the early 1980s, the Hunt brothers famously cornered the silver market, accumulating nearly one-third of the global silver supply. Their massive investment drove prices from $2/ounce to $50/ounce, but when they couldn't meet margin calls, the market collapsed.
Applying the Strategy to BIEL
Unlike silver, BioElectronics Corporation (BIEL) presents a unique opportunity with significantly lower capital requirements and no margin borrowing risk. Assuming 15 billion shares are in strong hands, that leaves approximately 10 billion shares available for accumulation—equivalent to a mere $2 million investment at $0.0002 per share.
Market Dynamics & Potential Price Action
Low Capital Requirement: Compared to the billions needed to manipulate the silver market, cornering BIEL’s available shares would require only pocket change relative to institutional investments.
No Margin Borrowing Risk: The Hunt brothers’ downfall was leverage—with BIEL, strategic accumulation would be fully capital-backed, mitigating collapse risk.
Upward Price Movement: As the 10 billion shares are acquired, price appreciation is inevitable—the key question is how much and how fast.
Catalysts for Growth
Reddit & Retail Investor Interest: If traction builds among the retail investing community (similar to past explosive penny stock movements), momentum could snowball rapidly.
Institutional Engagement: Increased distribution and medical adoption of RecoveryRx could attract larger institutional players, further stabilizing upward movement.
Conclusion
With strategic share accumulation, increasing revenues, and market excitement, BIEL could experience exponential appreciation—presenting a rare opportunity for early movers to corner a low-cap market with limited financial risk. Just sayin'...something for the BIEL VENTURE CAPITAL HEDGE FUND stakeholders to consider.
BIEL VENTURE CAPITAL HEDGE FUND
KEY STAKEHOLDERS: DR. DON BUFORD, DR. SREE KONERU, KEITH NALEPKA, OREL HERSHISER
Each key stakeholder should see RecoveryRx not just as a product, but as an opportunity for professional leadership and financial breakthrough. By distributing RecoveryRx and investing in BIEL shares, they cement their status as visionaries in medical innovation and create a powerful wealth-building opportunity in the highly lucrative medical device market.
Projected Outcomes:
1. Increased distribution of RecoveryRx among medical professionals.
2. Surge in BIEL stock accumulation, leading to exponential valuation growth.
3. Strengthened brand credibility through endorsements from industry leaders.
Executive Summary:
This plan aims to leverage the influence of key industry leaders—Keith Nalepka, Dr. Sree Koneru, Dr. Don Buford, and other medical professionals—to expand the distribution of RecoveryRx and drive investment in BIEL. By capitalizing on their networks and credibility, we can create a powerful movement that positions BIEL for exponential growth.
Strategic Business & Investment Framework for Key Stakeholders:
By leveraging their professional credibility, industry influence, and financial foresight, these individuals can accelerate RecoveryRx distribution, boost BIEL stock valuation, and secure first-mover advantages in a high-growth opportunity.
1. Keith Nalepka – Strategic Leadership & Global Expansion
As President of VLMS Global Healthcare and an ex-BIEL VP of Sales, Keith and VLMS are perfectly positioned to scale RecoveryRx distribution through major healthcare networks.
Immediate Strategy: Structure partnerships between BIEL and VLMS, integrating RecoveryRx into existing medical supply chains.
Investment Thesis: Keith’s direct experience with BIEL grants unique insights into its growth potential, making stock accumulation (by Keith and VLMS) a strategic financial move.
2. Dr. Sree Koneru – Technology & Medical Validation
As a former BIEL VP of Engineering and a high-level executive at Viant Medical, Dr. Koneru is critical for reinforcing technical credibility and expanding RecoveryRx adoption.
Industry Influence: His engineering expertise strengthens the case for RecoveryRx’s scientific legitimacy.
Stock Investment Strategy: His position on BIEL’s board aligns him with long-term value appreciation, making increased share accumulation (by Sree and Viant) a logical financial step.
Institutional Scaling: Collaborate with Viant Medical for large-scale manufacturing and distribution expansion.
3. Dr. Don Buford – Medical Advocacy & Market Expansion
Dr. Buford’s endorsement of RecoveryRx has sparked significant industry interest, as seen in his LinkedIn engagement.
Momentum Tactic: Capitalizing on enthusiastic responses to his post by establishing a formal RecoveryRx distributor network.
Revenue-Driven Investment Strategy: Encouraging physicians who show interest in distribution to also purchase BIEL shares, ensuring dual financial benefit.
MLB Connection Activation: Utilizing his ties within sports medicine to promote RecoveryRx adoption among MLB players and athletic trainers.
4. Orel Hershiser – MLB Endorsement & High-Profile Investment
Orel Hershiser, already a BIEL shareholder, can serve as a sports industry bridge, bringing in MLB investors and sports medicine practitioners.
Investor Activation Plan: MLB players invest in BIEL, seeing long-term financial growth potential in its expanding medical footprint.
Distribution Expansion Strategy: Partnerships with MLB training facilities and medical staff, integrating RecoveryRx into sports recovery protocols.
Media & Branding Enhancement: High-profile endorsements and interviews to accelerate visibility and credibility.
Leveraging Their Collective Influence:
By expanding RecoveryRx distribution and strategically accumulating BIEL shares, Keith (and VLMS), Sree (and Viant), Dr. Buford, and Orel Hershiser position themselves as industry pioneers, driving both medical innovation and wealth-building opportunities in the highly lucrative medical device market.
BIEL IS SIMPLE TO ANALYZE!
Q3 2021 was BIEL's only profitable quarter ($22,381) with $414,700 revenue (including $100k+ in covid relief funds). PROFITABILITY IS VERY CLOSE! Seems like $1.5 million annual revenue (or a $400k quarter) should do it, due to BIEL's extremely low operating costs and business model. Then the corresponding pps should hit .01 - and increase .01 for each additional $2.5 million annual revenue (P/E = 100). The $40 million tax-loss carry forward will make the first $40 million in profits tax free and accelerate the path to profitability. KISS - KEEP IT SIMPLE STUPID! 💋
THIS DISTINGUISHED GROUP COULD EASILY BECOME BIELIONAIRES!
1) LAST WEEK KEITH NALEPKA (EX-BIEL VP SALES) WAS PROMOTED TO PRESIDENT OF VLMS GLOBAL HEALTHCARE.
2) LAST WEEK A PRESITGIOUS GROUP OF DOCTORS/SURGEONS/MEDICAL WORKERS RAVED ABOUT RECOVERYRX.
https://www.linkedin.com/posts/donbufordmd_ever-heard-of-a-tens-unit-or-a-nerve-stimulator-activity-7333861518729465856-vdpb?utm_source=share&utm_medium=member_android&rcm=ACoAAD5fnnMBgcCqTZjoHiMob3xCmYJyZQN5d7A
3) RECENTLY DR. SREE KONERU (EX-BIEL VP ENGINEERING) WAS PROMOTED TO A HIGH-LEVEL MANAGEMENT POSITION AT VIANT MEDICAL AND SOON AFTER WAS APPOINTED TO THE BIEL BOARD OF DIRECTORS.
I think Keith and Sree already own over 100,000,000 shares and that Orel Hershiser also owns a significant amount. If they were to accumulate more, and the rest of the doctors/surgeons mentioned above invested accordingly, they could make BIEL run well over 10,000% (COPPER) in a matter of days/weeks - and much higher if Dr. Buford, Orel Hershiser and Keith Nalepka could tap into their MLB connections (or get some players to invest)!
DISTRIBUTORS AND INVESTORS ARE THE KEY TO SUCCESS!
It was great to see the fabulous replies to Dr. Buford's post. Responses like the following are the key to success for BIEL:
"I'm very excited to look into the possibility of carrying these devices and becoming a distributor."
While all the responses to Dr. Buford's post were excellent, this one deserves particular attention:
"I am also a believer! This thing simply works. I have no conflicts of interest, other than a small margin when my patients purchase one. It is truly impressive how well these work."
While the "small margin" can be remedied by increasing the unit cost, a better solution would be if the sellers and distributors purchased shares while the share price is so ridiculously low. The return on investment for the shares would be exponential (Amazon/Apple/Netflix - like) when the company reports (or hints about) increased revenues.
THE "WELLNESS MARKET" MAY BE THE BIGGEST OF ALL!
There were comments in the Dr. Buford discussion about potential uses for Actipatch/RecoveryRx that have not been FDA cleared. There have been many suggestions and testaments recently for using Actipatch/RecoveryRx "off label" as a "wellness" product (CHA-CHING $$$ without FDA complications - BIEL already has enough FDA clearances!). People have successfully used it for menstrual pain, migraines, diabetic neuropathy, restless leg syndrome (RLS affects 10% of adults worldwide), opioid reduction, bladder issues, etc. There is also huge potential for prostate issues (non-cancerous), as there is evidence that PEMF/PSWT therapy helps with Benign Prostatic Hyperplasia (BPH) symptoms.
❤️32 REASONS TO LOVE BIEL❤️
1. It's a real company with real products.
2. The company is not burning $$$ millions every quarter trying to get a product through the FDA wringer. They've accomplished FDA clearance (5) already.
3. The company is very close to profitability every quarter. BIEL will likely be profitable soon, if not already (a $400K revenue quarter should do it).
4. There is no toxic debt. The company is not sinking under death spiral financing.
5. Actipatch has thousands of excellent, mostly 5-star customer reviews.
6. The $40 million tax-loss carry forward will make the first $40 million in profits tax free and accelerate the path to profitability.
7. Insider Buying - Significant insider loans (and recent roll-overs) are equivalent.
8. Technical indicators (Golden Cross, Blue Sky Breakout, etc.) turning positive. Every bull run starts with this.
9. Bare bones expenses: about $750k/year for GENERAL AND ADMIN EXPENSES (salaries, utilities, R&D, Advertising, etc) with a burn rate of about $220k/year for Other Gen and Admin Expenses.
10. New utility patent (pending) for chronic pain inflammation (vagus nerve) - HUGE.
11. Accepted for use by the Veterans Administration.
12. BIEL has 5 FDA clearances with more pending.
13. Insurance coverage is expanding - currently covered by the UK National Health Service (and Taiwan?).
14. In business for over 20 years
15. Never reverse split.
16. Rapidly expanding in the veterinary/pet market - RECOVERYRX-VETERINARY could be a GOLDMINE!
17. New contract/partner rumors swirling.
18. Fed forecast to cut interest rates five times this year, which greatly benefits OTC stocks like BIEL.
19. The potential is mind-boggling - especially if Actipatch is identified as a "wellness product" for the applications not currently covered by the FDA clearances (menstrual, depression, migraines, restless leg, etc.).
20. Actipatch will be a Standard of Care product. Actipatch/RecoveryRX have a massive potential market - essentially every human on the planet AND their pets/animals (RecoveryRX Veterinary)!
21. The higher margin RecoveryRX is available by prescription.
22. A new distribution partner for the USA will be announced soon. The last time this happened (2021) BIEL surged 1,600%.
23. BIEL is optimizing the Netflix business model.
24. BIEL COULD HIT COPPER IN THE "BLINK OF AN EYE"!
25. PPS = .001. $800k annual revenue gets the pps out of the trips.
26. PPS = .003. BIEL GOES VIRAL (equivalent to 3,000% 10-year ROI gains in Apple and Amazon)!
27. PPS = .01. Achieved with $400k revenue quarter.
28. PPS = .02. 20,000% increase (with $5 million profit, P/E = 100).
28. PPS = .03. 30,000% increase (with $7.5 million profit, P/E = 100).
29. PPS = .04. 40,000% increase (akin to 10-year ROI in Bitcoin, with $10 million profit (P/E = 100).
30. PPS = .10. Achieved with $25 million profit (P/E = 100).
31. PPS = $1. After loans are paid off and a stock buyback is initiated.
32. See 1 - 31!
ACTIPATCH WILL BE A "STANDARD OF CARE" PRODUCT!
While Bitcoin has no underlying value (it's a speculative bubble like Dutch tulips in the 17th century or abstract art), Actipatch has FDA clearances for the treatment of knee, back, wrist, hips, ankles, plantar fasciitis, carpal tunnel and all musculoskeletal pain. Actipatch has incredible value, especially at the low price of $35 - with a much longer battery life (720 hours or several months if extended with the on/off button) than the competition! The Actipatch FDA clearances allow it to be sold over the counter (without a prescription). The higher margin RecoveryRX applications (post operative pain, edema, wound care, etc.) require a doctor order. Add in RecoveryRx-Veterinary and you have over 10 billion potential repeat customers - every adult and pet on the planet - every month!
BIEL's EASIEST, FASTEST AND MOST LIKELY PATH TO SUCCESS IS:
1) to generate a $400k revenue quarter (or convince investors it's imminent) - which would achieve cash flow positive/profitability and increase the pps to copper.
2) to generate a $1.5 million revenue year (or convince investors it's imminent).
3) if management hints Q1 2025 was profitable, or Q2 will be.
4) if investors value the new distribution and licensing partner for the OTC US market at $300k (gets the pps out of the trips when added it to the $496k of mostly international revenue reported for 2024). If the investor valuation is $1 million, then the pps hits COPPER!
BIEL:
1) gets out of the trips when some hints are dropped - triggering the Golden Cross (.0004)/Blue Sky Breakout (.0005) technical indicators.
2) PPS = .003 = 3,000% increase (better than Apple and Amazon over the past 10 years), when the new US distributor is announced - and then GOES VIRAL!
3) PPS = .02 = 20,000% increase with $5 million profit/P/E = 100.
4) PPS = .04 = 40,000% increase with $10 million profit/P/E = 100 (equivalent to Bitcoin over the past 10 years).
5) PPS = .10 with $25 million profit/P/E = 100.
RECOVERYRX-VETERINARY COULD/SHOULD BE A GOLDMINE!
The Assisi Loop sells over 300/month just on Amazon @ $329, with 1/20 the battery life. Assisi Loop customers are paying the equivalent of over $6,000 when you factor in the additional cost and lower battery life, but Assisi customers seem happy to pay it based on the numerous 5-star reviews. RecoveryRx/Veterinary should be sold as a two/pack - one applied on the vagus nerve and the other attached on the area of pain.
INSIDER BUYING - HUGE!
The best indicator for predicting a company's future is insider buying. The extensive insider loans (and recent roll-overs) identified in BIEL's annual reports basically have the same effect as insider buying. Insider loans are actually better, as they allow the company to avoid toxic lenders. The insider investment/market cap ratio for BIEL is higher than any other company on the market.
BIEL OPTIMIZING THE NETFLIX BUSINESS MODEL!
Netflix has increased over 325,000%, from .35 (on 10/9/02) to about $1,150 today!
1) Product price is about the same and Actipatch lasts as long as a monthly Netflix subscription (much longer when the on/off switch is utilized).
2) Actipatch/RecoveryRX has much larger market potential. While both are available to virtually every human on the planet, RecoveryRX Veterinary is also available to their pets! Also, the high margin RecoveryRX is available by prescription, and the "wellness market" is available for the aches and pains not covered by FDA clearances (menstrual, migraine, restless leg, depression, etc. - simply attach it over the vagus nerve!).
3) BIEL's product profit margins are much higher as their operating costs are virtually nothing compared to Netflix (no movie studios and actors required to constantly put out new content).
DR. OZ
The Dr. Oz effect will be interesting, considering his recent appointment as Administrator of the Centers for Medicare and Medicaid Services. When Actipatch was featured on the Dr. Oz show, it achieved record sales and sold out the inventory.
BIEL + DR. OZ = $$$ (see 6:25 mark)
https://youtu.be/qVvS2dC2-1s?si=OqYNG3__BRlz-NFF
PROSPECTUS
BIEL's low-cost OEM business model has put the company in position to be profitable soon such that if investors project for 2025:
1) Annual revenue of $800k - this will be a significant increase from the previous three years and get the pps out of the trips;
2) $1.5 million annual revenue (or a $400k quarter) - this will likely achieve cash flow positive/profitability and get the pps to copper.
3) BIEL's prospects for achieving a 1,000,000% increase in pps are better than any other company on the market right now!
4) The path to profitability will be accelerated by the tax-loss carryforward of about $40 million (no tax on first $40 million profit).
5) BIEL GOES VIRAL AT PPS = .003!
Market cap = $75 million at pps = .003, which would generate massive press (free marketing/advertising) in the news and financial media when they report that the pps increase is better than the gains in Amazon and Apple (3,000% over the past 10 years). It would solve all of BIEL's problems and create numerous opportunities for the company. The Reddit crowd would be all over it (generating massive free online marketing/advertising). If the company then declares profits would be used for a share buyback program (after paying off the loans), the pps would soar ($1+) and the rise would be sustained.
6) PPS = .02 = 20,000% increase - requires $5 million profit (P/E = 100). Profits will be accelerated by the tax loss carryforward (no tax on first $40 million profit)!
7) PPS = .10: Requires $25 million profit (P/E = 100). Profits will be accelerated by the tax loss carryforward (no tax on first $40 million profit).
BIEL IS THE NEXT AMAZON/APPLE (in terms of ROI)!
When BIEL hits .003, the return on investment for a .0001 buy (for those of us fortunate enough to get them recently) will be about the same as the 10-year ROI (3,000%) for Amazon and Apple (stocks I sold too soon). Microsoft 10-year ROI is ONLY 900%. BIEL can hit .003 in IN THE BLINK OF AN EYE, as $1.5 annual revenue (or a $400k quarter) should do it (due to BIEL's extremely low operating costs and business model). There are many indications that this will be accomplished soon, if it hasn't been already! We know that Taiwan, the VA, South Africa and Bulgaria are in progress, as is RecoveryRx-Veterinary in Europe (with the USA pending). Canada is expanding, New Zealand sales started March 1 and hopefully Australia will soon follow.
BIEL is a Venture Capitalist Dream! The opportunity to get in on the "next big thing", but with a company that has been in business for over 20 years (rather than a start-up). BIEL is probably the closest that any of us will get to having a venture capital kind of opportunity.
1) BIEL products have Standard of Care pain management potential for every adult and pet on the planet.
2) BIEL has 5 FDA clearances (with more pending) and the products work extremely well (some say like a miracle).
3) Upside ROI is huge (>10,000%) with minimal downside risk!
4) BIEL should be able to use their China manufacturer to ship directly to their international distributors and Viant for their USA sales to avoid tariffs.
BIEL HITS COPPER WHEN THE FOLLOWING OCCURS!
pps > .001 after management drops some positive hints. The Golden Cross (already achieved) and Blue Sky Breakout will get the technicians/chartists/Reddit crowd attention and the pps out of the trips;
pps > .01 after management drops some positive hints that convinces investors that break even/cash flow positive (annual rev = $1.5 mil) will be achieved, combined with the momentum from a 2021 like OTC run (fueled by the Reddit crowd);
pps > .04 after pr indicates the annual revs from Taiwan (in progress) can be valued at $10 mil+;
pps > .08 after pr indicates the annual revs from the VA (in progress) can be valued at $10 mil+;
pps > .12 after pr indicates the annual revs from RecoveryRx Veterinary (pending) can be valued at $10 mil+;
pps > .16 after pr indicates the annual revs from new contracts (distributors, partners, New Zealand, etc.) can be valued at $10 mil+;
Above pps values are based on P/E = 100
For P/E = 200, pps = .32
For P/E = 300, pps = .48
pps > $1 after loans are paid off and a stock buyback is initiated.
CATALYSTS (Details):
1) USA distribution partner announcement.
2) Taiwan - there are over 80 public hospitals and over 400 private hospitals in Taiwan. They have national health insurance and are rated the world's number one health system.
Assume 100 Taiwan hospitals order 100 Actipatch/RecoveryRx per month @$100 each for BIEL:
$100 x 100 hospitals x 100 x 12 mo = $12,000,000 rev/year.
Using profit = $10 mil and P/E = 100: PPS = .04.
Note: RecoveryRx Veterinary also appears to be in play in Taiwan.
3) 1000 Veterinarian Clinics (USA):
Conservatively assume each office orders 10/mo. @ $100 each for BIEL (Vet sells for $200, a bargain compared to Assisi):
1000 x 100 x 10 x 12 = $12,000,000 rev/year.
Note: RecoveryRx Veterinary also appears to be in play internationally.
4) Veterans Administration: There are over 1,000 VA facilities in the U.S. Conservatively assuming 100 VA hospitals order 100 RecoveryRx per month ($100 each for BIEL):
100 x 100 x 100 x 12 = $12,000,000 rev/year.
Sub-total for VA + VET = Using $20 mil (profit) and P/E = 100: PPS = .08!
TOTAL (Taiwan + VA + Veterinary + applying the tax loss carryforward):
pps = .12 (P/E = 100)
pps = .24 (P/E = 200)
pps = .36 (P/E = 300)
Additional revenue could be generated from new FDA clearances, vagus nerve patent, NPA, UK/Australia contract rumor, RecoveryRx Veterinary international sales, New Zealand, etc. Initiating a stock buyback program after all of the loans are paid off would propel the pps much higher (pps = $1).
BIEL FACT CHECK:
1) The basher/ambulance chasers repeatedly complain about the nearly 25 billion shares outstanding, but they can't provide a single reason why. It's irrelevant as it is accounted for in the VALUATION (pps) - 25 billion shares @.0002 = $5 million is the same valuation as 1 million shares at $5/share. NVIDIA has the same number of shares outstanding as BIEL, Apple and Amazon will soon have billions more (after the next split), and nobody is concerned! The stock market is all about valuation (outstanding shares x pps) - you buy if you think a stock is under-valued and sell if you think it is over-valued. Only amateurs/newbies/bashers do not understand this simple concept. Right now, investors feel BIEL is fairly valued between $2.5 - 5 million, but if news develops where investors feel $1 billion is fair value, you will see the BIEL pps rise accordingly (pps = .04). Some have tried to dispute this by changing the subject to dilution. BIEL has not diluted significantly in many years, and there is no indication it will in the future. The low pps is actually an advantage at this point, as it makes BIEL affordable to any investor (big and small). If you have $1,400 to invest, would you rather own 7 million shares of BIEL or 1 share of O'Reilly Auto Parts? The Reddit crowd would definitely choose BIEL.
2) BIEL's valuation is currently $5 million for revs of $496k (2024), which is undervalued compared to stocks with billion-dollar valuations but less revenue than BIEL (QUBT, for example, with a market cap of $2.2 billion on revenues of $373k). When people become aware of the benefits of PSWT/PEMF and the huge multi-billion-dollar drug free pain management market - that desperately needs FDA cleared Actipatch/RecoveryRx/RecoveryRx Veterinary- BIEL will SOAR!
3) BIEL has been in business for over 20-years and has NEVER done a reverse split, which is VERY IMPRESSIVE!
4) Supply/Demand - the majority of the outstanding shares are in tight hands, so the pps will move up like a rocket after ignition, as the supply of available shares will be less than the demand (SQUEEZE!). Shareholders can help fuel the blast off by locking up their shares with "good until cancelled sell orders" (@$1) so their shares cannot be borrowed by the short sellers, thereby further reducing the supply.
BUYOUT
Right now, I doubt anything under $50 million would be considered (accounting for loans, etc.). That's out of my range, but in the future - after the pps increases, loans are paid off and a share buyback is implemented - I could see a point where a group of shareholders could get together and leverage their shareholdings to make an offer. Years ago, Simpsonly and some other shareholders made an offer to Andy but were turned down. Not sure if Orel Hershiser was part of that group, but he is rumored to be a shareholder and a big fan of the products (would be a great influencer for BIEL).
LICENCE/PARTNER/MERGER?
The Signal Relief Patch (in business for a little over a year) costs about twice as much as the Actipatch, but is much less effective at reducing pain and will probably never gain FDA approval. However, they do have lots of money for marketing and advertising - their ads are on national TV every day, along with on-line media. They might be a good partner for Actipatch - we could use their advertising/marketing budget, and they could use Actipatch (integrated with their patch) to make their device more effective at reducing pain. It could work the way the KT licence was supposed to. Signal Patch is private now, so a merger with BIEL would give them quick access (compared to an IPO) to the stock market, where their venture capitalists would get a better return on their investment (than stay private).
REVIEWS (5 STAR)
BIEL technology works and sells WHEN people become aware of it and where to buy, as demonstrated by the Recovery Wave, which is Amazon's "Overall Pick" and a hot seller (over 700 per month) with rave reviews (STANDARD OF CARE like), such as:
Green Light ON...Pain is Gone!
Reviewed in the United States on May 5, 2025
I've been using this for a few years now and works great on my lower back and knee pain. I put one on my lower back before golf each week and zero pain. Highly recommend and don't leave home without it.
5.0 out of 5 stars Verified Purchase
Amazingly effective for such a little, simple device
Reviewed in the United States on October 29, 2024
I knew about these loops because a vet used an Assissi loop, this one’s big brother, to heal my agility dog’s back end when she sprained it badly. So I thought I’d try this smaller, cheaper and more portable unit to help with healing and pain from a fractured sacrum that had been hurting for 9 months. I had to leave this device on for several hours at a time. After about two hours on I noticed pain diminishing the first time I wore it. Now after about a month of sporatic use (ie, only when I had pain or did activities I knew that brought on pain) I am living mostly pain free! I also have been doing my PT exercises and they help too, but the pain wasn’t diminishing much with exercises alone. Another advantage of this unit is that it doesn’t shoot a current through your body like a tens unit, which I find very disagreeable. I will keep a KT Wave Recovery loop on hand for times when I need it.
RecoveryRX is also getting great reviews (May 2025):
Steven Ray Garcia Owner/Operator-Sandlot Medical: "This is a great product. I work with a couple top Plastic Surgeons in Scottsdale, and Recovery RX is part of their breast augmentation recovery protocol."
IS BIEL THE NEXT MSFT?
Those that bought one share of Microsoft at the IPO price of $21 saw their investment increase to $210,000 recently (10,000 X). Someone buying 1 million shares of BIEL @.0002 would see their $200 investment grow to $2,000,000 (pps = $2) with equivalent growth. Is this possible? Absolutely, after BIEL becomes profitable, pays off their loans and then implements an aggressive stock buyback program!
SUPPLEMENT 1 (courtesy of beacham)
I think what is happening is BIEL has ‘a deal’ w/ one of the suppliers/distributors to CMMS and/or the VA. I also think we have an emerging contract relationship w/ Viant and that is the reason Dr. Sree Koneru is on our BOD.
These presumptions (opinions) solve a lot in terms of logistics and financials. For manufacturing, it removes the uncertainty of a China-based supplier of product. Taiwan is a flashpoint and relations w/ China are strained. Viant has international reach that can supply product to any of our distributors worldwide w/o all the drama and tension, not to mention shipping time, of having a manufacturer thousands of miles away in a potentially hostile situation. How this ties into the paucity of Raw Materials expenditures over the last 4 yrs is a good question. We keep CICD for the Asian distribution but should circumstances change, we have Viant. They also have a Design & Development division. It’s a smart move.
Working w/ a ‘local’ supplier to CMMS and/or the VA takes the buyout scenario off the table for now. It does, however, give BIEL some certainty in terms of revenue and, if/when announced, would do wonders for the share price.
The logistics of this are complicated, complex, time sensitive and politically charged, involving not only the nuts and bolts but official approvals as well. I think the Atlanta sites are a pilot project / launch-point to work out the myriad details. Working through a supplier who has already done the paperwork to work w/in the CMMS and/or VA bureaucracies is a huge bonus. They would ‘simply’ add our products to their catalog. Doing the legwork to make that happen would be their responsibility and thus freeing us to focus on supplying product to them for their distribution to the numerous CMMS and/or VA locations.
It would also explain having an NDA and the near total silence that ensues. Nobody needs or wants an army of bashturds crawling up your backside agitating for the impossible. The scope and magnitude of this project is enormous, beyond words. CEO Kelly Whelan has not been given enough credit, in my opinion. And all of this work must be done under the radar, by legal necessity, as per an NDA. Lots of moving parts and endless details. When CEO Kelly says they are working, I believe her.
SUPPLEMENT 2 (courtesy of beacham)
Let’s assume that BIEL will get the CMS and the VA contract. If/when that announcement(s) takes place, whether simultaneously or separately, the explosion in the share price will make Mt. Vesuvius look like a backyard firecracker on the 4th of July. Now, I ask you, would that make you stay ‘mum’ on any of the details??? Yea, me too.
The share price would not hit copper in a week. It would happen before lunch. By the time you entered an order at a specific price, the price will have jumped to the next level. Either buy at ‘market’ or forget it. The price would explode. Dare to dream and imagine.
3331 has been restricted to one post per day (for months) which is often deleted.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Ask ADVFN Intelligence (AI)
GetSeriousOK
8 hours ago
walker_429
8 hours ago
Hawk05
1 day ago
Hot Features
Premium
